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ABSTRACT 
Hepatic microsomal cytochrome P-450 has previously been postulated to 
be an important factor in determining the rates of hepatic haem bio-
synthesis and biodegradation. The basis for this proposal is that the 
haem moiety of cytochrome P-450 appears to be in equilibrium between 
binding to apocytochrome P-450 and existing in some form in the central 
hepatic pool of haem concerned with the regulation of the haem metabolic 
pathways. Consequently, any change in the levels of hepatic cytochrome 
P-450 would be anticipated to affect the pathways of hepatic haem bio-
synthesis and biodegradation. 
At the onset of this project, relatively few chemical agents were known 
to destroy cytochrome P-450 (either by degradation of the haem moiety 
of, or dissociation of the haem moiety from hepatic microsomal cytochrome 
P-450) and to affect hepatic haem biosynthesis and/or haem biodegradation 
(e.g. AIA, Cs2 and various metals). We thus attempted to further estab-
lish the relationship between the ability of compounds to affect hepatic 
cytochrome P-450 and to affect hepatic haem metabolism 2-':1_ vivo, using 
the three anaesthetic agents~ fluroxene, halothane and trichloroethylene. 
During the preparation of this thesis, several other chemicals have been 
found which destroy cytochrome P-450 and affect hepatic haem metabolism 
(e.g. norethisterone, morphine). 
In addition to the above, it has been attempted to clarify the roles of 
the degradation of different forms of cytochrome P-450 and of the 
different mechanisms of destruction of cytochrome P-450 in the control 
of hepatic haem metabolism. The three anaesthetic agents, fluroxene, 
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halothane and trichloroethylene were chosen for study since they destroy 
cytochrome P-450 by ~pparently different mechanisms. Both fl uroxene 
and trichloroethylene specifically degrade the haem moiety of different 
forms of cytochrome P-450, but fluroxene converts the haem moiety of 
cytochrome P-450 to an N-substituted porphyrin, while TCE apparently 
degrades the haem into uncoloured products. In contrast, halothane 
appears to degrade the haem of cytochrome P-450 to uncoloured products 
as well as to facilitate the dissociation of haem from intact cytochrome 
P-450. 
In general, acute administration of the anaesthetic agent confirmed the 
relationship between the destruction of cytochrome P-450 and the control 
of hepatic haem metabolism, Acute administration of fluroxene, tri-
chloroethylene and halothane caused increases in the rates of hepatic 
haem biosynthesis and/or haem biodegradation, The suggestion that the 
effects of these compounds on hepatic haem metabolism were due to their 
ability to destroy cytochrome P-450 was supported by the observation 
that 2,2,2-trifluoroethyl ethyl ether (TFEE) and tetrachloroethylene, 
which are analogues of the anaesthetics, and do not or only slightly 
affect the levels of hepatic cytochrome P-450, had little or no effect 
on hepatic haem metabolism in vivo, 
The ability of the three compounds to destroy cytochrome P-450 by differ-
ent mechanisms is apparently reflected in the details of their effects on 
hepatic haem metabolism. A single injection of fluroxene causes the 
induction of both hepatic haem biosynthesis and biodegradation, whereas 
acute trichloroethylene treatment results in an increase in hepatic haem 
biodegradation, but little or no change in hepatic haem biosynthesis. 
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In contrast, halothane, which appears to cause both the degradation 
and the dissociation of cytochrome P-450, resulted in cyclical changes 
in hepatic haem biosynthesis and biodegradation in a manner which corres-
ponded to the differing effects of this compound on cytochrome P-450. 
Although the effects of acute administration of these compounds on 
hepatic microsomal cytochrome P-450 appeared to play an important role 
in determining their effects on hepatic haem metabolism, the effects 
of chronic administration of the anaesthetic agents on hepatic haem bio-
synthesis appeared to result from their ability(or not)to inhibit a 
particular enzyme of the haem biosynthetic pathway. Since a block in 
the haem biosynthetic pathway generally results in the induction of ALA~ 
synthetase and an accumulation of haem precursors before the enzymatic bloc~ 
chemicals which cause the inhibition of a particular enzyme of haem bio-
synthesis, result in the induction of a state of experimental porphyria 
in animals which may resemble a type of human genetic porphyria. 
Chronic administration of fluroxene and trichloroethylene resulted in 
the induction of experimental porphyria in animals by virtue of their 
ability to inhibit particular enzymes of the haem biosynthetic pathway 
whereas halothane did not appear to affect any specific enzyme of haem 
biosynthesis and did not induce an experimental porphyria in animals 
but caused cyclical changes in hepatic haem metabolism. 
Chronic fluroxene administration resulted in the inhibition of the haem 
biosynthetic enzyme, uroporphyrinogen synthetase, and induced an 
experimental porphyria in animals which closely resembled Acute Inter-
mittent Porphyria (AIP). Chronic trichloroethylene treatment appeared 
to affect the enzyme uroporphyrinogen decarboxylase and induced an 
viii 
experimental porphyria which resembled human Porphyria Cutanea Tarda 
(PCT). It is therefore proposed that chronic administration of fluroxene 
and trichloroethylene may be useful as convenient model systems for 
studying the human genetic porphyrias. 
From the results presented in this thesis, it is clear that the effects 
of chemicals on hepatic microsomal cytochrome P-450 and hepatic haem 
metabolism are extremely varied, Several factors appear to affect the 
relationship between the ability of a compound to destroy cytochrome 
P-450 and its ability to affect haem metabolism. It is therefore not 
possible at this time to predict the detailed effects of a drug on 
hepatic haem metabolism. However, it is hoped that this study has 
helped to substantiate the proposal that chemicals which destroy hepatic 
microsomal cytochrome P-450, will affect hepatic haem metabolism~ vivo 
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I INTRO DU CTI ON 
l. l. AIM 
The purpose of this thesis was to investigate the effects of certain 
anaesthetic agents, viz. fluroxene, halothane and trichloroethylene, 
and their analogues, on haem biosynthesis and biodegradation. It was 
anticipated that some of these compounds might affect haem biosynthesis 
and biodegradation as a result of their metabolic activation by and 
subsequent destruction of cytochrome P-450 in vivo. Consequently, the 
introduction section of the thesis will consider not only the metabolism 
and metabolic activation of these compounds (and of xenobiotics in 
generai) by drug metabolizing enzymes and in particular by cytochrome 
P-450, but it will also cover mechanisms for the degradation of cyto-
chrome P-450. Details of the pathways for and the control of hepatic 
haem biosynthesis and biodegradation will be discussed as well. The 
possible role of cytochrome P-450 in the regulation of haem biosynthesis 
and in physiological disorders thereof will be considered. 
1.2. DRUG METABOLISM 
Living organisms are subjected to a wide range of xenobiotics, viz. 
chemical compounds such as drugs, carcinogens and environmental pollut-
ants which are foreign to the organism in as much as they are not syn-
thesized endogenously. In mammals, the metabolic transformation of 
these compounds occurs primarily in the liver and is catalyzed by 
several groups of non-specific enzymes known collectively as drug-
metabolizing enzymes (Table l .1). Lower levels of these enzymes 
2 
are also found in other organs and tissues such as the kidney, intestine, 
lung, adrenal and skin (1), but for many compounds the liver is respon-
sible for more than 95% of their metabolism. 
The role of the drug metabolizing enzymes~ vivo is essentially to 
protect the body against an accumulation of lipid-soluble exogenous com-
pounds by converting them to polar hydrophilic molecules which are 
water-soluble and are thus more readily excreted via the kidneys into the 
urine than are the parent molecules. In general, the pathway by which 
many lipid-soluble compounds are rendered more water-soluble occurs in 
two distinct phases (Fig. 1.1): 
FIGURE 1. 1. The general pathway for the metabolism of xenobiotics. 
Oxidation 
Xenobiotic (Insoluble in H2o, Toxic) 
Phase I 
Oxidized (or hydroxylated) 
Xenobiotic 
(Slightly soluble) 
Conjugation Phase II 
Conjugated Xenobiotic (Very soluble, not toxic) 
Phase I - The oxidation of the compound by reactions such as dealkylation, 
deamination and hydroxylation (Table 1 .1). 
Phase II -The conjugation of the oxidized intermediate or of the parent 
compound with a small polar molecule (e.g. glucuronic acid, 
glutathione or sulphate) (Table 1 .1) (2,3). 
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TABLE 1.1 
HEPATIC METABOLISM OF DRUGS 
Reaction 
Oxidation of aliphatic 




Reduction of azo-, 
nitro- compounds 
Oxidation and reduction 
I of al coho 1 s, a 1 dehydes 
and carboxylic acids 
Oxidation of amines 
Hydrolysis of esters 
I 




Conjugation with sulphate, 
glycine, other amino 
acids; acetylation and 
methylation 



































Although the metabolism of xenobiotics is generally a detoxification 
process, there are a number or compounds which are converted by the 
drug metabolizing enzymes to more toxic, and in some cases, carcinogenic 
metabolites. For example, vinyl chloride is converted by enzymes of 
the liver to the metabolites chloroethylene oxide and/or chloroacetalde-
hyde (4,5), which are thought to mediate the toxicity and carcinogenicity 
of the parent compound; and the anaesthetic agent fluroxene is metabolized 
by hepatic enzymes to the toxic metabolite 2,2,2-trifluoroethanol (6). 
1 .2.1. Cytochrome P-450 
Phase I of drug metabolism (Fig. 1.1) is catalyzed predominantly by the 
cytochrome P-450 enzyme system which is found within the deeper layers 
of the endoplasmic reticulum+ (1 ,7). Cytochrome P-450 is a group of 
haem-containing isoenzymes~ which were so named because of the strong 
absorbance near 450 nm associated with the carbon monoxide - ferrocyto-
chrome P-450 complex (8). This group of enzymes appears to be amongst 
+ Homogenization of the liver tissue disrupts the endoplasmic reticulum. 
The resultant segments of the endoplasmic reticulum form spontaneously 
into small vesicles known as hepatic microsomes. These may be 
separated from the liver homogenate by ultracentrifugation. The 
microso~al fraction thus obtained from the liver is a convenient 
natural source of cytochrome P-450 for laboratory studies .:!.!2. vitro. 
* In this thesis the term 1 cytochrome P-450' has been used as the general 
name for all of the isoenzymes of cytochrome P-450. Where required, 
specific terminology has been used to indicate a particular form of 
cytochrome P-450 - e.g. the term 'the major form of cytochrome P-450 
induced by .... ' refers to the isoenzyme which is induced by, for 
example, phenobarbital (cf. Section 1 .2.1.5). 
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the most versatile protein catalysts known since they are capable of 
catalyzing the metabolism of a wide variety of drugs and other foreign 
compounds (9) - these include aryl hydrocarbons, polycyclic hydro-
carbons, barbiturates, halogenated hydrocarbons, amphetamines and poly-
chlorinated biphenyls. Cytochrome P-450 is also involved in the 
metabolism of a number of physiological substrates such as fatty acids, 
alka~es (10) and steroids 01). 
In addition to the broad substrate specificity of cytochrome P-450, 
another striking feature of this group of enzymes is its ability to 
catalyze such a diversity of reactions; for example, both oxidative and 
reductive reactions are catalyzed, including an extremely wide variety 
of the former, such as hydroxylation, deamination, sulphoxidation, 
dealkylation and oxidation (Table 1.2)(12, 13). The oxidative reactions 
catalyzed by cytochrome P-450 may all be regarded as proceeding via 
hydroxylation reactions even though in many cases the final product may 
not be hydroxylated (Table 1 .2). Thus, in general, the overall reaction 
catalyzed by the cytochrome P-450 drug metabolizing enzymes is considered 
to be of the following form: 
SH + NADPH + + --> SOH + [l J 
where SH represents the substrate and SOH its hydroxylated product. 
According to equation [1], cytochrome P-450 catalyzes the oxidation of 
one mole of substrate and the oxidation of one mole of NADPH for each 
mole of molecular oxygen that is consumed. However, in experiments 
conducted with hepatic microsomes, the theoretical stoichiometry of 
1 :l :1 is not always observed due to the oxidation of NADPH by other 
enzymes, the oxidation of endogenous substrates by cytochrome P-450, 
or the uncoupling of the cytochrome P-450 enzyme system. 
6 
TABLE 1.2 





CO-NH-C6H5 ~~) CH3-CO-NH-C6H4-0H 
Aliphatic hydroxylation 
[OH] 







) ROH + CHi 
[OH] 
R-CH(NH 2)-CH3 [R-C(OH)(NH2)-CH3] ---1 R-CO-
CH3 + NH3 
Sulphoxidation 
[OH] 
R-S-R' -- [R-SOH-R']+----) R-SO-R' + H+ 
N-Oxidation 
[OH] 
(CH 3)3N [(CH3)3NOH]+ ----J (CH3)3NO 
+ H+ 
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NADPH is the preferred electron donor for cytochrome P-450 dependent 
reactions (both oxidative and reductive). Other reductants such as 
NADH and ascorbate may also act as electron donors but are generally much 
less effective than NADPH in supporting cytochrome P-450 mediated reactions 
(14). For NADPH-dependent drug metabolism, electrons are passed from 
NADPH to cytochrome P-450 by the electron carrier NADPH-cytochrome P-450 
reductase+ (15) as shown in equation [2]:* 




NADH + NADH - cytochrome E.s reductase + cytochrome E.s 
where NADH is the electron donor, NADH- cytochrome E.s reductase+ and 
cytochrome E.s function as the electron carriers in the passage of 
electrons from NADH to cytochrome P-450 (Equation (2)) (15). 
1.2.l.l. Binding of compounds to cytochrome P-450 
Several drugs and other foreign compounds have been shown to bind non-
covalently to hepatic cytochrome P-450 producing characteristic absorbance 
difference spectra (16-18). The binding of a compound to a specific 
binding site on the enzyme alters the environment of the haem moeity (19), 
giving rise to absorbance changes in the visible region of the spectrum. 
The most commonly observed types of difference spectra for binding to cyto-
chrome P-450 have been identified as type I, type IR and type II (Fig. 1.2)(20) 
+ Both NADPH-cytochrome P-450 reductase and NADH-cytochrome E.s reductase 
are also known as cytochrome£ reductases because they can transfer 
electrons to the non-physiological acceptor cytochrome£ via cytochrome E.s· 
* Only the last part of equation [2] differs between the oxidative and 
reductive reactions catalyzed by cytochrome P-450 (cf. Figs. 1.3 and 1.4). 
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The type I difference spectrum is a spectral manifestation of the forma-
tion of a substrate - cytochrome P-450 complex since compounds which 
bind to the type I binding site of cytochrome P-450 are with few excep-
tions metabolized by cytochrome P-450. The type I difference spectrum 
has been shown to arise from substrate-induced conformational changes in 
the protein which alter the environment of the haem moiety and alter the 
spin state of the haem iron atom of ferricytochrome P-450 from a low 
spin to a high spin state (19). 
The type IR spectrum reflects the conversion of the haem iron atom of 
ferricytochrome P-450 from a high spin to a low spin state (20) the 
opposite change in spin state to that seen with type I binding. Thus, 
binding of compounds to the type IR binding site of cytochrome P-450 
results in the production of a spectrum which is the exact reverse of 
the type I difference spectrum (Fig. 1 .2), but results in the exclusion 
of these compounds from metabolism by cytochrome P-450. 
In contrast to type I and type IR spectral changes~ the type II spectral 
change results from direct binding of the added xenobiotic to the 
central iron atom of the haem of cytochrome P-450 and leads to the 
formation of a modified ferrihaemochrome in the low spin state (Fig. 1.2) 
(18,20). Type II compounds compete with oxygen as a ligand for the 
haem iron atom of ferrocytochrome P-450 and thereby inhibit cytochrome 
P-450 catalyzed oxidative metabolism (21). Examples of type II binding 
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FIGURE 1.2. Difference spect~al changes in hepatic microsomes. 
Sample cuvette contains microsomes and compound, and reference cuvette 
microsomes alone. Spectral changes represented: type I (----); 
type I I ( ... _ -) ; and type IR (---). 
10 
1.2.1.2. Cytochrome P-450 catalyzed oxidative metabolism 
The binding of a compound to the type I binding site of cytochrome 
P-450 is considered to be the first step in the cytochrome P-450 
dependent metabolism of a compound. The accepted mechanism for the 
cytochrome P-450 mediated oxidative metabolism (hydroxylation) of a 
compound is depicted diagrammatically in Fig. 1.3 and may be summarized 
as follows: 
1. A substrate binds to cytochrome P-450 to form a high-spin ferri-
cytochrome P-450 enzyme-substrate complex. 
2. The enzyme-substrate complex undergoes a one electron reduction to 
a ferrocytochrome P-450 - substrate complex (23,24). 
3. The ferrous enzyme-substrate complex reacts with molecular oxygen 
to form an oxyferrous enzyme-substrate complex (21,25). 
4. This complex undergoes a second reduction stage, forming a super-
oxide ferrous enzyme-substrate intermediate which is a resonance 
form of the hydroperoxo ferric enzyme-substrate complex (26,27). 
5. The hydroperoxo ferric enzyme-substrate complex decomposes by 
heterolytic scission of the 0-0 bond to produce water and a ferric 
enzyme-monooxygen species which is in resonance with the ferryl ion 
complex (Fe4+o-) (26,28). 
6. The hydroxylated product is released from its binding site on cyto-
chrome P-450, thus regenerating cytochrome P-450 in the low spin 
ferric state (29). 
1.2.1 .3. Cytochrome P-450 catalyzed reductive metabolism 
Cytochrome P-450 has recently been shown to also participate in the 





















































































































































N-oxides (33) and organic nitro and azo compounds (30). Such a 
reductive function of cytochrome P-450 is rather unexpected in view 
of the high affinity of the enzyme for molecular oxygen. However, 
it has been suggested that the oxygen concentration in cells may be 
quite low (32), especially in the centre of the liver lobules, and 
this allows lipophilic reducible compounds with relatively high oxi-
dation potentials to compete effectively with oxygen for electrons 
at the active site of cytochrome P-450. Under these conditions, viz. 
low oxygen tension, the reduced form of cytochrome P-450 can transfer 
one or two electrons directly to the substrate, resulting in substrate 
reduction and the oxidation of ferrocytochrome P-450 to the ferric state 
(32,34,35). 
Recently, much attention has been focused on the metabolism of poly-
halogenated ~iphatic compounds since they are widely used as solvents 
and often have pronounced anaesthetic properties. The metabolic trans-
formation of these compounds in the liver results in the formation of 
toxic metabolites which are thought to be responsible for the liver 
damage promoted by these compounds in animals and man (32). There is 
now direct evidence that polyhalogenated alkanes can undergo oxidative 
and reductive metabolism catalyzed by cytochrome P-450 in vivo and in 
vitro (31 ,32 ,36). For most halocarbons, the extent by which reductive 
metabolism occurs under normal conditions, viz. high oxygen tension, is 
unknown but it appears to be a function of the oxygen concentration in 
the liver cell (32) since anaerobic conditions enhance the reductive 
metabolism of these compounds (32,37). However, for compounds such as 
carbon tetrachloride and hexachloroethane, which cannot be metabolized 
oxidatively due to their lack of any hydroxylatable C-H bonds, only the 
13 
reductive pathway can occur,and this has been confirmed by the identi-
fication of their exhaled volatile reductive metabolites (32). 
The mechanism of the cytochrome P-450 mediated reductive metabolism of 
these halocarbons has recently been investigated (32) and is thought to 
proceed via two subsequent one-electron reductions, forming first a 
radical and then a carbanion. The carbanion can subsequently form 
an alkene via B-elimination of a halide anion (32). The mechanism of 
the cytochrome P-450 catalyzed reductive metabolism of hexachloroethane 
is shown below in Fig. 1.4. Analagous reaction schemes have also been 
proposed for the reductive metabolism of carbon tetrachloride (38) and 
halothane (see Fig. 1.8) (39). 
It has been proposed that the radical species thought to be generated 
during reductive metabolism of halogenated alkanes could initiate lipid 
peroxidation and thereby cause membrane damage as the crucial event of 
hepatotoxicity (32). Although the formation of radicals during the 
metabolism of some halocarbons has been demonstrated (38,40), the 
influence of these radical species on hepatotoxicity requires further 
investigation. 
1.2.1.4. Multiplicity of cytochrome P-450 
As mentioned earlier (Section l .2.1), cytochrome P-450 is comprised of 
a group of haemoproteins. Although the debate - 'Cytochrome P-450 -
one form or many' raged in the 1960's and 1970's, the evidence available 
presently overwhelmingly supports the existence of multiple forms of 
cytochrome P-450 in microsomes prepared from liver and other tissues 



































































































































































































































































































































































identified, purified and characterized (29). In rat liver, for 
example, using criteria such as disc gel electrophoresis, absorption 
maxima, immunological and catalytic properties and partial amino acid 
sequence, from five to seven forms of cytochrome P-450 have been 
identified (41,42). These isoenzymes of cytochrome P-450 differ in 
their apparent minimum molecular weights (29), absorbance maxima, 
substrate specificities and physical properties+ (43-47). The induc-
tion of cytochrome P-450 with different agents has played an important 
role in the identification of cytochrome P-450 isoenzymes and will be 
considered in the following section (Section 1.2.1.5). 
1.2.1.5. Induction* of cytochrome P-450 
Cytochrome P-450 is highly inducible, i.e. its activity can be greatly 
increased by exposure to a wide variety of xenobiotics (9, 49-51). In 
fact, more than 200 compounds including steroid hormones, drugs, insecti-
cides and carcinogens are now known which stimulate drug metabolism in 
experimental animals and man (1, 29). Various inducing agents often 
selectively increase the levels of one particular form of cytochrome 
P-450 from the mixture of different forms of cytochrome P-450 present 
in hepatic microsomes (29, 41). For this reason, the use of different 
inducing agents has not only played a major role in establishing the 
+ At present no systematic nomenclature is available for the multiple 
forms of cytochrome P-450. The nomenclature presently used by 
various laboratories to designate different forms of cytochrome P-450 
is neither uniform nor based on a common rationale and several of the 
forms purified in one laboratory are probably identical to forms 
isolated by other laboratories (41). 
* The term induction in mammalian systems has been defined by Schimke 
and Doyle (48) as an increase in the ratio of the rate of protein 
synthesis over the rate of protein degradation. 
16 
existence of multiple forms of cytochrome P-450 but has also provided a 
very useful tool for the study of the role of a particular form of 
cytochrome P-450 in the metabolism and toxicity of xenobiotics. 
Perhaps the most widely used inducing agent for cytochrome P-450 is 
phenobarbital. Administration of phenobarbital induces the isoenzyme 
termed 'the major phenobarbital-inducible form of cytochrome P-450' 
(Table 1.3) (41). This isoenzyme is responsible for the metabolism of 
a wide variety of substrates (15), including N,N-dimethylaniline, 
parathion, benzamphetamine and N,N-dimethylphentermine (41). Pheno-
barbital also enhances hepatic drug metabolism because it increases 
proliferation of the endoplasmic reticulum and the weight of the liver 
and, in addition, it increases the levels of NADPH-cytochrome c reductase, 
cytochrome ~5, cytochrome P-450 and phospholipid per mg of microsomal 
protein (29). 
Administration of 3-methylcholanthrene or s-napthaflavone leads to the 
induction of the isoenzyme termed 'the major 3-methylcholanthrene -
inducible form of cytochrome P-450' (Table 1.3) (41), which is also kno1tm 
as cytochrome P-448 or cytochrome P1-450. This form of the enzyme is 
primarily responsible for the metabolism of polycyclic aromatic hydro-
carbons such as 3,4-benzpyrene, 7-ethoxycoumarin, 7-ethoxyresofurin 
and zoxazolamine (41). 
The 'PCN (pregnenolone l6a-carbonitrile) - inducible form of cytochrome 
P-450' (Table 1.3) (41) is another species of cytochrome P-450 which, on 
the basis of several criteria, is a different isoenzyme than either the 
major phenobarbital- or 3-methylcholanthrene-inducible forms (41). 
































































































































































































































































































































































































































































































































































































































































































































































































































































































pyri ne ( 41). Other well-known inducing agents include iso-saffrole, 
saffrole, ethanol, diethyl ether and aroclor 1254, to mention but a 
few. 
1.2.2. Metabolism of fluroxene and TFEE 
Fluroxene (2,2,2-trifluoroethyl vinyl ether) (Fig. 1.5) is a volatile 
anaesthetic agent which was introduced into clinical practice in 1953 
(52). It was widely used, and it developed a reputation for safe 
clinical usage in man with no evidence of organ toxicity (53,54). 
More recently, however, laboratory tests showed fluroxene to be toxic 
and lethal to many animal species (55-60) and to man under certain 
circumstances (61-64). Following, and perhaps as a result of these 
studies, the manufacturers withdrew fluroxene from the market in 1977. 
The major site of fluroxene metabolism in vivo is the liver, and the 
first step of its metabolism appears to be catalyzed by hepatic micro-
somal cytochrome P-450 ~ vivo and~ vitro (65,66). From initial 
experiments in our laboratory using hepatic microsomes from differently 
induced rats (i.e. phenobarbital or 3-methylcholanthrene induced), it 
was concluded that the major form of cytochrome P-450 induced by 
phenobarbital was primarily responsible for the binding and metabolism 
of fluroxene, whereas the major form of cytochrome P-450 induced by 
3-methylcholanthrene apparently did not bind or metabolize fluroxene 
(66). However, recent experiments using highly purified isoenzymes 
of cytochrome P-450 have shown that fluroxene is metabolized by the 
major form of cytochrome P-450 induced by 3-methylcholanthrene but at 
a much lower rate than the metabolism of fluroxene by the major 
phenobarbital-inducible form of cytochrome P-450 (67). 
19 
The proposed pathways of the biotransformation of fluroxene and its 
saturated analogue, 2,2,2-trifluoroethyl ethyl ether (TFEE), are shown 
in Fig. 1 .5(68). The major products from the cytochrome P-450 mediated 
metabolism of fluroxene have been identified as 2,2,2-trifluoroethanol 
(TFE) and glycolaldehyde (Fig. 1.5)(58,69). TFEE, on the other hand, 
is metabolized by hepatic microsomal cytochrome P-450 to TFE and 
acetaldehyde (Fig. 1.5) (67,68). In both pathways, TFE is subsequently 
metabolized~ vivo by microsomal UDPGA-transferase to 2,2,2-trifluoro-
ethanol glucuronide and by cytosol alcohol dehydrogenase plus aldehyde 
dehydrogenase to trifluoroacetic acid (Fig. 1.5) (6,70). 
Investigations into the hepatotoxicity of fluroxene and TFEE have led to 
the proposal that the deleterious effects of these compounds arise from 
their metabolism by hepatic microsomal cytochrome P-450 to the toxic 
metabolite TFE (Fig. 1.5) (55,59,69,71). The major evidence in support 
of this proposal is the observation that phenobarbital pretreatment of 
animals potentiates the toxic effects of both fluroxene and TFEE, presumably 
as a result of the phenobarbital mediated elevation in the activity of the 
cytochrome P-450 enzyme system causing an increase in the rate of metab-
olism of these compounds to TFE (70,72). Furthermore, treatment of 
animals with TFE results in toxic symptoms identical to those that 
develop after fluroxene or TFEE treatment (73). 
The relative lack of toxicity of fluroxene in man as compared to animal 
species has been attributed to differences in the rates for the metab-
olism of TFE (58,74), since the major metabolites in the urine of 
animals after fluroxene anaesthesia are free and conjugated TFE (75), 
whereas in man the major urinary metabolite is the relatively innocuous 
20 

















Abbreviations: cyt., cytochrome; TFE, 2,2,2-trifluoroethanol; 
TFEE, 2,2,2-trifluoroethyl ethyl ether. 
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compound, trifluoroacetic acid (Fig. 1.5) (76). 
Recently, in an attempt to explain the observed metabolic products 
and toxic effects of fluroxene, a detailed mechanism for the conversion 
of fluroxene to TFE and glycolaldehyde was proposed on the basis of 
molecular orbital calculations (Fig. 1.6) (69). The postulated mechanism 
for the metabolism of fluroxene involves an initial cytochrome P-450 
catalyzed epoxidation of the double bond of fluroxene (Fig. 1.6). This 
is followed by a non-enzymic protonation of the epoxide. The protonated 
epoxide can then undergo a nucleophilic attack by water via an SN2 
mechanism or an acid catalyzed hydrolysis of the epoxide (SNl mechanism) 
which would produce a glycol hemiacetal derivative (Fig. 1.6). Ether 
cleavage of the glycol hemiacetal derivative would generate TFE and 
glycol aldehyde in a stoichiometric 1 :1 ratio (Fig. 1.6) (69). 
1 .2.3. Metabolism of halothane 
Halothane (CF3CHBrCl) (Figs. 1.7, 1.8) which was introduced as an 
anaesthetic agent in 1956 (77) is currently the most widely used volatile 
inhalation anaesthetic in the world, due to the relative safety of its 
action and its ease of administration. However, halothane anaesthesia 
has occasionally been associated with acute hepatic injury in man (78). 
Attempts to discover the cause of this toxicity have led to extensive 
studies of the metabolism of halothane both in animals and man (79,80). 
Halothane has been shown to be metabolized to a considerable extent in 
humans, with as much as 24% of the administered dose of halothane being 
excreted as non-volatile urinary metabolites (81 ,82). Trifluoroacetic 
acid has been identified as the major urinary metabolite of halothane 
22 
FIGURE 1.6. Postulated metabolic pathways for fluroxene catalyzed 
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(Fig. 1.7) (82,83): Other non-volatile metabolites of halothane 
include N-trifluoroacetyl ethanolamine (84), N-trifluoro-2-amino-
ethanol and N-acetyl-S-(2-bromo-2-chloro-l ,1-difluoroethyl)-cysteine 
(85) as well as bromide, chloride and fluoride ions (Fig. 1.7) (86,87). 
Recently two novel metabolites were detected in the exhaled gases of 
experimental animals and man following halothane administration (34,88). 
These volatile metabolites were identified by Mukai et~- (88) as 
2-chloro-l ,1-difluoroethylene and 2-chloro-l ,1 ,l-trifluoroethane 
(Figs. 1.7, 1.8). 
The first and some of the subsequent steps in the biotransformation of 
halothane take place primarily in the liver (34). There appear to be 
parallel metabolic pathways for the biotransformation of halothane, 
viz. an oxidative pathway and one or more reductive pathways (Figs. 
1.7, 1.8) (34,39,82). 
The first step in the oxidative metabolism of halothane (Pathway I, 
Fig. 1.7) is thought to involve cytochrome P-450 catalyzed oxygen in-
sertion on carbon number two to form 2-bromo-2-chloro-2-hydroxy-
l ,1 ,1-trifluoroethane which rapidly decomposes to trifluoroacetyl 
chloride. The latter compound can react spontaneously with water to 
form trifluoroacetic acid (34), or it can react with phosphatidyl 
ethanolamine to yield the non-volatile urinary metabolite, N-trifluoro-
acetyl ethanolamine (Fig. 1.7) (85). The cytochrome P-450 mediated 
oxidation of halothane (Pathway I, Fig. 1.7) is generally considered 
to be a detoxification reaction and is, under normal conditions (viz. 
normal oxygen tension), the major pathway by which halothane is 



































































































































































































































































































































































































































The first step of the reductive pathways of halothane metabolism 
(Pathways II and III, Fig. 1.7) are also catalyzed by cytochrome P-450 
(34,39,89). These pathways are thought to be associated with halothane 
mediated hepatotoxicity in animals and humans (39). Although the 
importance of these pathways under normal oxygen tension is not known, 
they are greatly enhanced under low oxygen tension (39,90). 
The reduction of halothane via Pathway II (Fig. 1.7) results in the 
formation of the intermediate, F2C=CBrCl, a highly toxic compound which 
can react with cellular constituents, or with glutathione to yield 
N-acetyl-S(2-bromo-2-chloro-l ,l-difluoroethyl)-L-cysteine (Fig. 1.7) 
(34,85,91). Alternatively, and of far greater importance in explaining 
halothane toxicity, is the cytochrome P-450 mediated reduction of halo-
thane by Pathway III (Figs. 1.7, 1.8) which leads to the formation of the 
volatile metabolites 2-chloro-l ,1-difluoroethylene and 2-chloro-l ,1 ,1-
trifluoroethane. 
A reaction scheme has been proposed for the formation of 2-chloro-l ,1-
difluoroethylene and 2-chloro-l ,l ,1-trifluoroethane which involves con-
secutive one electron reductions (Fig. 1.8) (39) analagous to the 
proposed cytochrome P-450 catalyzed reduction of haloalkanes such as 
carbon tetrachloride (38) and hexachloroethane (Fig. 1.4) (32). 
According to this mechanism (39), free radical species generated during 
the cytochrome P-450 mediated reduction of halothane (Fig. 1.8) may bind 
to microsomal proteins and unsaturated lipids and thereby initiate halo-





























































































































































































































































































































































































1.2.4. Metabolism of trichloroethylene and tetrachloroethylene 
Trichloroethylene (HC1C=CC1 2) (Fi9. 1.9) is at present in use as a 
general anaesthetic agent and analgesic. It is also extensivly used 
in industry, primarily as a dry-cleaning solvent and metal degreasing 
agent. Although trichloroethylene is not considered as a potent 
hep3totoxin (92), exposure to trichloroethylene has been reported to 
result in central nervous system depression, hepatotoxicity and nephro-
toxicity (93,94) and large doses of this anaesthetic agent have occasion-
ally proved fatal to humans (93-95) and to laboratory animals (96). 
Interestingly, trichloroethylene was the first inhalation anaesthetic 
agent found to undergo biotransformation ..:!_.!!_ vivo (97,98). Trichloro-
ethylene was shown to be metabolized by the liver to chloral hydrate 
(Fig. 1.9) (97-99) which is subsequently transformed to trichloroacetic 
acid and 2,2,2-trichloroethanol glucuronide , which are the major urinary 
metabolites of trichloroethylene (Fig. 1.9) (97,100). Other known 
metabolites of trichloroethylene include trichloroethylene-oxide, 
glyoxylic acid, formic acid and CO (Fig. 1.9) (100). Trichloroethylene 
is unique among inhalation anaesthetics since in addition to its own 
anaesthetic properties, its metabolites,chlorw hydrate and 2,2,2-tri-
chloroethanol also possess hypnotic properties which may contribute 
to the overal 1 anaesthetic effect of the parent compound (97). 
The first step in the oxidative metabolism of trichloroethylene to chloral 
has been shown to be catalyzed by hepatic microsomal cytochrome P-450 in 
vivo and in vitro (97,99,101-103). It was originally thought that the 
product of the enzyme catalyzed reaction was the epoxide, trichloro-
ethylene-oxide which subsequently formed chloral via an internal non-
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enzymic rearrangement. However, it has recently been proposed that 
trichloroethylene-oxide is not an obligate intermediate in the metabolism 
of trichloroethylene to chloral in vitro (100,104). Alternatively, it 
has been suggested that the metabolism of trichloroethylene by cytochrome 
P-450 proceeds via a transition state in which trichloroethylene is 
bound to an activated oxygen of cytochrome P-450 (cf. Fig. 1.9) (100). 
This transition state may then rearrange either to chloral or trichloro-
ethylene-oxide as shown in Fig. 1.9. Thus the cytochrome P-450 
catalyzed oxidation of trichloroethylene to chloral is thought to in-
volve chlorine migration within an oxygenated trichloroethylene - cyto-
chrome P-450 transition state and not via trichloroethylene-oxide 
(Fig. 1.9) (100). Trichloroethylene-oxide is proposed to decompose to 
form glyoxylic acid, formic acid and CO (Fig. 1.9) (100). On the 
basis of the above proposals, a reaction scheme for the metabolism of 
trichloroethylene has been suggested and it is shown diagrammatically 
in Fig. 1.9 (100). 
The metabolism of trichloroethylene is thought to result in the formation 
of reactive metabolites which bind irreversibly to proteins (105) and 
nucleic acids (106), thereby promoting the deleterious effects observed 
after trichloroethylene administration. In support of this proposal, 
studies of trichloroethylene metabolism have shown a direct correlation 
between the extent of metabolism of trichloroethylene and its hepato-
toxicity (101,105,107). According to earlier reports, the reactive 
metabolite presumed to be responsible for these effects was trichloro-
ethylene-oxide (101,105,108). However, Miller and Guengerich (100) 
suggest chloral, dichloroacetyl chloride and formyl chloride as well 
as trichloroethylene-oxide to be possible reactive metabolites that 
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might bind irreversibly to protein and nucleic acids. Further research 
is required to elucidate the roles of these compounds in such binding 
and their significance in trichloroethylene mediated hepatotoxicity. 
Tetrachloroethylene (Cl 2C=CC1 2), a symmetrically substituted analogue 
of trichloroethylene, is widely used industrially as a dry-cleaning 
and metal degreasing agent (109,110). As a consequence of its relatively 
low chemical reactivity and toxicity, tetrachloroethylene is often 
utilized industrially in preference to trichloroethylene (110,111). 
Tetrachloroethylene is primarily metabolized in the liver to trichloro-
acetic acid, which is the major urinary metabolite of this chlorinated 
ethylene~ vivo (112). Hepatic microsomal cytochrome P-450 is known 
to catalyze the first step of the biotransformation of tetrachloro-
ethylene (113) which is thought to proceed as follows:-





0 0 / \. n 




H20 ~c1 3cco2H (112,113) 
Tri ch 1 oro 
acetic acid 
The lower chemical reactivity and lower toxicity of tetrachloroethylene 
compared to that of trichloroethylene is proposed to be a consequence of 
the lower rate of metabolism of tetrachloroethylene (114-116) and may 
also be due to its conversion to less reactive metabolites+ (113). 
+ Tetrachloroethylene-oxicte is believed to be much less reactive than 
the epoxides of unsymmetrically substituted chlorinated ethylenes 
such as trichloroethylene and vinyl chloride (116,117). 
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1.3. DESTRUCTION OF CYTOCHROME P-450 
Recent studies have revealed that the metabolism of some substances by 
cytochrome P-450 is accompanied by a decrease in the levels of this 
enzyme and consequently in diminished activities of the cytochrome P-450 
drug metabolizing system (16,67,118). In many cases, this process is 
relatively specific for cytochrome P-450 in that other microsomal 
enzymes such as cytochrome E_s and NADPH-cytochrome £ reductase are 
affected only slightly or not at all (16, 118-121). This process is 
in contrast to the general devastation of proteins caused by highly 
toxic agents such as carbon tetrachloride which promote lipid peroxi-
dation (120,122). 
From studies of the destruction of cytochrome P-450, it has been found 
that the substrate must be catalytically activated by cytochrome P-450 
in order for the destruction of this enzyme to occur (16,119,120). 
The catalytic involvement of cytochrome P-450 in its own destruction 
is demonstrated by the requirement for NADPH and by the inhibition of 
this process by potent inhibitors of cytochrome P-450 such as SKF 525A, 
CO and metyrapone (119,121,123). There are two clearly distinct ways 
in which substrates can destroy cytochrome P-450; viz [1] degradation of 
the haem moiety of cytochrome P-450 by its chemical modification, or 
[2} dissociation of the unmodified haem moiety from the apoprotein of 
cytochrome P-450 as a result of alteration of the structure of apocyto-
chrome P-450 (120,123). 
Degradation of the haem moiety of cytochrome P-450 is demonstrated 
experimentally by a quantitative decrease in the levels of hepatic 
microsomal haem which is equal to the observed decrease in the levels 
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of hepatic microsomal cytochrome P-450 (16, 119, 124), while the apo-
protein of cytochrome P-450 may be unmodified (125, 126). Substrates 
which exhibit this degradative potential are in general unsaturated 
compounds such as ethylene and propyne (67, 127, 128). 
Several recent experiments have shown that in some cases (but not all -
cf. vinyl chloride (127)), the haem which is lost from cytochrome 
P-450 is converted to a haem derivative (or 'green pigment') (127, 129) 
thought to be formed by alkylation of the haem group of cytochrome 
P-450 by an activated form of the substrate (127, 129). Although 
several different substrates have been used to demonstrate this 
phenomenon, the haem derivative which is formed is, in each case, an 
N-substituted protoporphyrin IX, the structure of which is consistent 
with a mechanism involving cytochrome P-450 mediated activation of 
the substrate leading to covalent attachment of a portion of that 
substrate to a nitrogen atom of the protoporphyrin framework of 
prosthetic haem (127, 129-131). Degradative substrates may also be 
isoenzyme selective (67, 128, 132) either as a consequence of suicide 
inhibition or of the relative sensitivity of different isoenzymes to 
degradation. 
The second way in which compounds can destroy cytochrome P-450 is by 
facilitating the dissociation of haem from the apoprotein moiety of 
cytochrome P-450. These compounds appear to elicit their effects 
by modifying the structure of apocytochrome P-450, thereby reducing 
the affinity of haem for the apoprotein moiety (133). In this 
process a loss of cytochrome P-450 is accompanied by little or no loss 
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of hepatic microsomal haem (16, 120) and,as a result, an increase in 
the amount of labile free haem+ is observed in the livers of experi-
mental animals after treatment with the destructive agent (16, 120, 133). 
1.3.1. Destruction of cytochrome P-450 by fluroxene 
The metabolism of fluroxene by hepatic microsomal cytochrome P-450 
results in destruction of this enzyme~ vivo and~ vitro (72, 135). 
This destructive process appears to involve the chemical modification 
of the haem moiety of cytochrome P-450 since the loss of microsomal 
haem observed after fluroxene treatment is equivalent to the loss of 
cytochrome P-450 (132), while the apoprotein moiety remains unchanged 
(125). The unsaturated vinyl portion of the fluroxene molecule has 
been shown to be essential for the destructive potential of this 
anaesthetic because neither TFEE, nor the metabolites TFE, trifluoro-
acetic acid or trifluoroacetaldehyde degrade cytochrome P-450 (65, 67, 
72, 135). These results also demonstrate that the fluorine substi-
tuer.ts of fluroxene are not responsible for the observed destruction 
of cytochrome P-450, but it has been suggested that their presence 
might enhance the destruction of microsomal cytochrome P-450 ~ vivo 
by fac·ilitating accessibility of this xenobiotic to hepatic microsomal 
cytochrome P-450 (67). 
Since fluroxene itself does not degrade cytochrome P-450, it was pos-
tulated that a reactive intermediate, originally believed to be an 
+ The appearance of a cytochrome P-420 peak (Fig. 1 .10) is detectable 
in the microsomal preparations of animals treated with the destructive 
compound (123) and is thought to be representative of free haem bound 





















































































































































































































































epoxide arising from the metabolism of the vinyl moiety of fluroxene, 
was responsible for the degradation of cytochrome P-450 (135). 
Although attempts to isolate the epoxide of fluroxene have failed (69), 
it has recently been proposed that the reactive species involved in 
the fluroxene mediated degradation of cytochrome P-450 is not the 
epoxide but rather an intermediate which is formed after cytochrome 
P-450 catalyzed epoxidation of the double bond (69). 
Recently, a mechanism for the formation of this reactive species and 
its subsequent degradation of cytochrome P-450 was proposed (69). It 
was calculated that the fluroxene epoxide (formed by cytochrome P-450 
catalyzed oxidation of fluroxene (Fig. 1.6) would be stable and could 
diffuse away from the active site of the enzyme (69). In soiution 
the epoxide could be protonated and decompose to products (Fig. 1.6). 
However, some molecules of the fluroxene epoxide could become protonated 
at the active site of the enzyme and the resulting carbonium ion (Fig. 
1.6) could react with a nucleophilic moiety on the haem of cytochrome 
P-450, thus destroying the enzyme. This mechanism would explain the 
observation that the fluroxene mediated destruction of cytochrome P-450 
is not a first order reaction (69, 136) and that the destruction 
process and the generation of product occur simultaneously (69). 
The degradation of hepatic microsomal cytochrome P-450 by fluroxene 
results in the formation of a haem derivative or'green pigment' (123, 
132) which accumulates in the microsomes of fluroxene treated animals 
(132). This 'green pigment' was originally postulated to be an N-
substituted porphyrin formed by covalent attachment of a portion of 
fluroxene to the haem moiety of cytochrome P-450 (137). Although 
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attempts were made in our laboratory to isolate and characterize this 
haem derivative, Kunze et~- (138) published a report showing that 
the exact structure of the pigment is N-(2-oxoethyl )protoporphyrin IX. 
This result is consistent with a mechanism in which the cytochrome 
P-450 catalyzed epoxidation of the unsaturated bond of fluroxene is 
accompanied by alkylation of the prosthetic haem of cytochrome P-450 
(138). 
The extent of the fluroxene mediated degradation of cytochrome P-450 
is found to be enhanced by inducers of cytochrome P-450 such as pheno-
barbital (67, 69, 132). However, different isoenzymes of cytochrome 
P-450 appear to be preferentially degraded by fluroxene after different 
types of induction (132). In microsomes from phenobarbital induced 
animals, degradation appears to be non-specific with regard to different 
forms of cytochrome P-450, whereas in microsomes from 3-methylcholan-
threne treated animals, the major form of cytochrome P-450 induced by 
3-methylcholanthrene is preferentially degraded (132). Furthermore, 
studies with highly purified isoenzymes of cytochrome P-450 have shown 
that the form of cytochrome P-450 induced by s-naphthaflavone (or 
3-methylcholanthrene) is more susceptible to fluroxene potentiated 
metabolic destruction than is the form of cytochrome P-450 induced by 
phenobarbital (67, 128). Thus, although the destruction of both forms 
of cytochrome P-450 is extensive, the relatively lower rate of metab-
olism of fluroxene by the form of cytochrome P-450 induced by s-na~htha-
flavone (or 3-methylcholanthrene) indicates that this isoenzyme of cyto-
chrome P-450 produces less activated metabolite but is more sensitive 
to destruction (67). 
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1.3.2. Destruction of cytochrome P-450 by halothane 
The metabolism of halothane by hepatic microsomal cytochrome P-450 
is accompanied by a reduction in the levels of hepatic cytochrome 
P-450 in vivo and in vitro (16, 78, 139). This process appears to 
be specific for cytochrome P-450 since the levels of other hepatic 
microsomal proteins, such as cytochrome E.s and NADPH-cytochrome £ 
reductase, are not affected by halothane (16, 78). 
Studies of the metabolism of halothane in vitro have shown that the 
loss of hepatic microsomal cytochrome P-450 exceeds the loss of 
hepatic microsomal haem and that the loss of cytochrome P-450 is 
accompanied by an increase in cytochrome P-420 (Fig. 1.10) after 
halothane treatment (16). These results indicate that the halothane 
mediated decrease in the levels of hepatic cytochrome P-450 in vitro 
appears to be partly due to the modification of the haem moiety of 
cytochrome P-450 and partly due to the dissociation of the haem moiety 
from cytochrome P-450 (presumably as a result of halothane mediated 
denaturation of the apoprotein) { 16). 
1.3.3. Destruction of cytochrome P-450 by trichloroethylene and 
tetrachloroethylene 
Trichlorcethylene metabolism has been shown to result in the degradation 
of hepatic microsomal cytochrome P-450 in vivo and in vitro (99, 100, 
107). It would appear that trichloroethylene specifically degrades 
the haem moiety of hepatic microsomal cytochrome P-450 since the tri-
chloroethylene mediated decrease in the levels of hepatic microsomal 
cytochrome P-450 is accompanied by an identical decrease in the levels 
of hepatic microsomal haem (99). 
38 
Since trichloroethylene itself does not degrade cytochrome P-450 (99), 
it was postulated that the epoxide, trichloroethylene-oxide (thought 
to be formed by cytochrome P-450 catalyzed oxidation of trichloro-
ethylene (Fig. 1.9)) was the reactive species responsible for the 
degradation of the haem of cytochrome P-450. However, evidence has 
recently been obtained which shows that epoxide metabolites, including 
trichloroethylene-oxide, play at most, a minor role in the destruction 
of cytochrome P-450 mediated by the parent o1efins (100, 127, 140). 
It appears likely therefore, that a reactive intermediate is generated 
during or after cytochrome P-450 catalyzed epoxidation of the double 
bond (69, 100). 
Different types of inducing agents appear to affect the metabolism of 
trichloroethylene by hepatic microsomal cytochrome P-450 and the deg-
radation of the haem of cytochrome P-450 by trichloroethylene to 
similar extents (99). Induction of cytochrome P-450 with phenobarbital 
enhances the metabolism of trichloroethylene as well as the trichloro-
ethylene mediated degradation of cytochrome P-450, whereas induction 
of cytochrome P-450 with 3-methylcholanthrene reduces the metabolism 
of trichloroethylene and the trichloroethylene mediated degradation of 
cytochrome P-450 (99). 
As opposed to trichloroethylene, tetrachloroethylene, the fully 
chlorinated analogue of trichloroethylene, does not affect the levels 
of hepatic microsomal cytochrome P-450 and haem in vitro (113) and only 
slightly decreases the levels of hepatic microsomal cytochrome P-450 
~ vivo (141). The less severe effects of tetrachloroethylene on the 
levels of hepatic microsomal cytochrome P-450 may reflect a lower rate 
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of metabolism of tetrachloroethylene and/or conversion to a less 
reactive metabolic intermediate than trichloroethylene (113, 117). 
1.4. HAEM BIOSYNTHESIS 
The biosynthesis of haem has been extensively studied (for reviews, 
see 142-146). The overall pathway of haem biosynthesis is outlined 
in Fig. 1.11 and may be summarized as follows: 
The first step in the pathway is the condensation of succinyl CoA (147) 
and glycine (148) to form o-aminolevulinic acid (ALA) (Fig. 1. 11) (149). 
This reaction takes place in the mitochondria (150-152) and is catalyzed 
by ALA-synthetase (153) which is the rate-limiting enzyme of the haem 
biosynthetic pathway in normal circumstances (153, 154). ALA-synthe-
tase is thought to exist as a dimer with a molecular weight of approxi-
mately 120 000 (155). Pyridoxal-5 1 -phosphate, which is an essen-
tial cofactor for this enzyme, is bound to ALA-synthetase more strongly 
than either of its substrates (151, 156-158). Although the major 
fraction of ALA-synthetase is found in the mitochondrion (150, 159, 160), 
some ALA-synthetase is also found in the cytosol but it is thought to 
be a precursor form in transit to the mitochondrion (161). 
The second step of the haem biosynthetic pathway, viz. the condensation 
of two molecules of ALA to form the monopyrrole porphobilinogen (162), 
takes place in the cytoplasm (Fig. 1.11) (163). The enzyme which 
catalyzes this reaction, ALA-dehydratase (164, 165), consists of eight 
identical subunits arranged as a pair of tetramers (166). Z 2+ . n ions, 
which bind to the sulfydryl groups of the enzyme, are required for 
maximum activity (167). 
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Four molecules of porphobilinogen are condensed to form the octa-
carboxylic tetrapyrrole known as uroporphyrinogen (Fig. 1.11). Two 
different stereo-isomeric forms of uroporphyrinogen are formed during 
the biosynthesis of haem, viz. the type I and type III isomers (Fig. 
1. 11). The formation of uroporphyrinogen III is catalyzed by the 
action of two independent, sequentially acting enzymes known as uro-
porphyrinogen I synthetase and uroporphyrinogen III cosynthetase (Fig. 
1. 11) (143, 168-170). However, in the presence of uroporphyrinogen I 
synthetase alone, four molecules of porphobilinogen are converted to 
one molecule of uroporphyrinogen I (Fig. 1.11) (171-173), whereas 
uroporphyrinogen III cosynthetase alone cannot accept either porpho-
bilinogen or uroporphyrinogen I as a substrate (170,174). 
Uroporphyrinogen III, which contains 8 carboxyl groups, undergoes step-
wise enzymatic decarboxylation of all four of its acetic acid side 
chains to produce coproporphyrinogen III (Fig. 1.11) (175, 176). It 
appears that a single enzyme, known as uroporphyrinogen decarboxylase, 
effects the four successive decarboxylations proceeding in a clockwise 
manner about the molecule (177-179). Uroporphyrinogen I is also de-
carboxylated by this enzyme to coproporphyrinogen I (Fig. 1.11), but 
this reaction proceeds at a slower rate than the decarboxylation of the 
type III isomer (178-182). The oxidation of uro- and coproporphyrinogen 
intermediates to their corresponding porphyrins (Figs. 1.11 and 1.12) 
results in the exclusion of these compounds from the haem biosynthetic 
pathway (180). 
The conversion of coproporphyrinogen III to protoporphyrinogen IX 
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(Fig. 1.11) involves an oxidative decarboxylation of two adjacent 
propionate groups to yield two vinyl moieties. This process takes 
place in the mitochondria and is catalyzed by coproporphyrinogenase 
(183). This enzyme is specific for the type III isomer of copropor-
phyrinogen, i.e. it does not react with the type I isomer of copro-
porphyrinogen (184). The subsequent oxidation of protoporphyrinogen 
IX to protoporphyrin IX (Figs. 1.11, 1.12) is catalyzed by the enzyme 
protoporphyrinogen oxidase (185-187). 
The final step in haem biosynthesis is the incorporation of a ferrous 
ion (Fe2+) into protoporphyrin IX (Fig. 1. 11). This reaction is catalyzed 
by the mitochondrial enzyme, ferrochelatase (188, 189). 
The haem thus formed combines with various apoproteins to yield the haem 
containing enzymes of the liver such as cytochromes, catalase, tryptophan 
pyrrolase and peroxidase. As can be seen in Fig. 1. 11, the type I porphy-
rinogens are by-products of the haem biosynthetic pathway since only the 
type III porphyrinogens are intermediates in the biosynthesis of haem. 
The major by-products of the pathway, viz. the type I porphyrins, as 
well as small amounts of the type III porphyrins are normally excreted 
in urine and faeces (190). Porphyrins with more than 4 carboxyl groups 
including uroporphyrin (Fig. 1.12) are predominantly excreted in the 
urine (191), while those with less than 4 carboxyl groups, e.g. proto-
porphyrin (2 carboxyl groups) (Fig. 1.12) are eliminated exclusively in 
the faeces (192). Coproporphyrin (4 carboxyl groups) (Fig. 1.12) 
appears in both urine and faeces (190). Differences in the routes of 
excretion of porphyrins are brought about through differences in their 
water solubility. 
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FIGURE 1.12. Porphyrin Ring System 
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In addition, small amounts of the other metabolic intermediates of haem 
biosynthesis, viz. ALA and porphobilinogen (193) and various type I 
and III porphyrinogens (Fig. 1. 11) (194) are excreted in the urine of 
normal mammals. 
Since most aerobic cells can synthesize haem, it is likely that small 
amounts of porphyrins are formed in virtually all tissues of the 
mammalian organism. In relation to the overall extent to which haem 
is synthesized in the body, the amounts of porphyrins and porphyrin 
precursors that are excreted in normal individuals are very small, there-
by attesting to the efficiency of the haem biosynthetic pathway (190,195). 
1.5. HAEM BIODEGRADATION 
The first step in the catabolism of haem (Figs. 1.13, 1.14) is catalyzed 
by the microsomal enzyme, haem oxygenase (196). The binding of haem 
by haem oxygenase confers a transitory haemoprotein nature to the 
enzyme (197). The newly formed haemoprotein can then accept reducing 
equivalents from NADPH via microsomal NADPH-cytochrome £ reductase (198). 
Haem oxygenase thus functions as the terminal oxygenase in the oxidative 
cutabolism of haem (199), with haem acting as both substrate and co-
enzyme (200,201). 
The first step in the oxidation of haem by haem oxygenase is assumed to 
be the hydroxylation of the a-methene carbon of protohaem, which is then 
followed by cleavage of the haem ring to yield biliverdin IXa (Figs. 
1. 13, 1. 14) (200,202). The precise way in which oxygen is involved in 
the reaction has not yet been determined, but the formation of a haem 
ion-oxygen complex is thought to take place on the enzyme prior to the 
cleavage of the haem ring (201,203). 
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The subsequent step in the biodegradation of haem is the conversion of 
biliverdin IXa to bilirubin IXa (Figs. 1.13, 1. 14) by biliverdin reduc-
tase, which is present in excess in liver cytosol (196, 204). Bili rubi n 
IXa is conjugated to glucuronic acid and eventually deconjugated before 
it is excreted via the bile of humans and animals (Fig. 1.14) (205). 
1.6. HEPATIC REGULATION OF HAEM BIOSYNTHESIS AND BIODEGRADATION 
The biosynthesis of haem is regulated by the activity of the first enzyme 
in the haem biosynthetic pathway, ALA-synthetase*(Fig. 1.11) (150, 206). 
Furthermore, the amount and activity of this enzyme are regulated by 
haem, the end-product of the pathway, in a manner which involves 
repression of the synthesis of the enzyme at a transcriptional (207) 
or post-transcriptional level (208), and/or by a mechanism which 
prevents the transfer of precursor ALA-synthetase from the cytosol to 
the mitochondria (208, 209). Thus haem controls its own rate of syn-
thesis by controlling the activity of ALA-synthetase. Haem also regu-
lates the rate of its biodegradation since haem oxygenase, which catalyzes 
the first and rate-controlling step in the pathway for the biodegradation 
of haem, is inducible by haem (133). 
The results of recent experiments, using isolated hepatocytes, suggest 
that a central pool of hepatic haem exists in the cytosol into which 
newly synthesized haem is incorporated and from which haem is drawn 
for the synthesis of hepatic haemoproteins,and for the degradation of 
haem to bilirubin (210, 211). It has been postulated that the size of 
this central 'free' haem pool regulates the activity of ALA-synthetase 
(211-215), and of haem oxygenase (133,211, 215), thereby controlling 
* Uroporphyrinogen synthase has been shown to act as a secondary rate 
controlling step in haem biosynthesis. 
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the rate of haem biosynthesis and haem biodegradation (Fig. 1.15). 
In part, the levels of haem in the hepatic regulatory haem pool are thought 
to be controlled by hepatic cytochrome P-450. It has been suggested that 
hepatic microsomal cytochrome P-450 dissociates into haem plus apo-
protein with the haem in equilibrium between the regulatory'free' 
haem pool and apocytochrome P-450 (Fig. 1.15) (133, 210,211, 216). 
This proposal is supported by the observation that exogenous haem is 
incorporated into intact apocytochrome P-450 ~ vivo and is thought to 
mix with newly synthesized haem in the 'free' haem pool prior to its 
incorporation into cytochrome P-450 (216-218). 
In the liver, large quantities of haem are required for the synthesis 
of haemoproteins, particularly hepatic microsomal cytochrome P-450 (219) -
more than 50% of haem synthesized in the liver is utilized in the formation 
of cytochrome P-450 (133, 142, 210). Thus the dissociation or degradation 
of haem from cytochrome P-450 should have a significant effect on the size 
of the regulatory haem pool and consequently exert an effect on haem 
biosynthesis via ALA-synthetase activity and/or haem biodegradation via 
an effect on the activity of haem oxygenase (Fig. 1.15). This phenomenon 
has been shown to occur in the presence of chemicals such as allyl-iso-
propylacetamide (AIA) which degrade the haem moiety of cytochrome P-450 





































































































































































































l. 7. PORPHYRIA 
Metabolic disorders in the regulation of haem biosynthesis and bio-
degradation are known to occur. These disorders, which manifest them-
selves as a group of diseases which are known as the porphyrias, are 
characterized by an accumulation of the intermediates of the haem bio-
synthetic pathway,..:!_.~. ALA, porphobilinogen and the porphyrins (220). 
Since the major sites of haem biosynthesis in mammals are the liver and 
the erythroid elements of bone marrow, the porphyrias are classified 
according to whether the bulk of excessive porphyrin production takes 
place in the liver or bone marrow; viz. hepatic porphyria or erythro-
poietic porphyria respectively (Table 1.4) (221). 
Since most of the porphyrias are autosomal dominant genetic diseases, 
it can be shown that each of the porphyrias represents a different inborn 
error of metabolism in haem biosynthesis (Fig. 1.16) {221). There is, 
therefore, in each type of porphyria a different and characteristic 
pattern of excretion of haem precursors (Table 1.5) (145, 222). Because 
the disorders are generally hereditary, any enzyme defect would be present 
in all somatic cells, and indeed such defects have been found in fibro-
blasts, amniotic cells and peripheral blood, in addition to the liver 
and bone marrow (223, 224). 
The activity of ALA-synthetase, the rate controlling enzyme in haem bio-
synthesis, is markedly raised in most varieties of human porphyria with 
the exception of Porphyria Cutanea Tarda, where the increase is relatively 
small (Table 1.4) (225). Since the activity (226) of ALA-
synthetase is thought to be regulated by haem through a negative feedback 
control (Fig. 1.15), a genetic defect in the haem biosynthetic pathway 
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TABLE 1.4 
CLASSIFICATION OF HUMAN PORPHYRIAS 
HEPATIC PORPHYRIAS 
I) GENETIC AUTOSOMAL DOMINANT PORPHYRIAS 
* 1 ) Acute Intermittent Porphyria (AIP) 
2) Variegate Porphyria (VP) ( S. A. Porphyria) 
* 3) Hereditary Coproporphyria (HCP) (rare) 
4) Porphyria Cutanea Tarda (PCT) 
II) ACQUIRED PORPHYRIA 
1) Porphyria Cutanea Tarda (PCT) 
ERYTHROPOIETIC PORPHYRIAS 
1) Congenital Porphyria 
2) Erythropoietic Protoporphyria 
* 


















































































































































































































































































































































































































































































































































































ABNORMALITIES OF THE HAEM BIOSYNTHETIC PATHWAY ASSOCIATED WITH THE 























EXCRETED IN EXCESS 
+ 6-Aminolevulinic acid 
t Porphobilinogen* 
t 6-Aminolevulinic acid 
t Porphobilinogen 
t Uroporphyrin III 
t Coproporphyrin III 
t Protoporphyrin IX* 
t 6-Aminolevulinic acid 
t Porphobilinogen 
t Uroporphyrin III 
t Coproporphyrin III* 
t Uroporphyrin * 
t 7-Carboxylic porphyrin 
t 6-Carboxylic porphyrin 
t 5-Carboxylic porphyrin 
----------~----------~-----------
* The haem precursor immediately preceding the enzymatic block is 
excreted in the greatest amounts. 
+ Where an increase in the activity of ALA-synthetase is found, it is 
generally thought to be a secondary effect, resulting from the decrease 
in haem levels due to the block in the haem biosynthetic pathway. 
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which lowers the rate of synthesis of haem could interfere with the 
feedback control of haem biosynthesis and lead to the stimulation 
of the activity of ALA-synthetase (227). Inhibition of haem 
synthesis at one of the steps in the biosynthetic chain will lead to 
the differences in the excretoryproducts observed in the various types 
of porphyrias; the major intermediate which will accumulate is that 
immediately preceding the enzymatic block (Fig. 1. 16) (Table 1.5) (228). 
1.8. CHEMICALS AND PORPHYRIA 
Studies of experimental hepatic porphyrias have provided valuable insight 
into the mechanisms by which the pathways of haem biosynthesis and bio-
degradation are regulated in the liver. The experimental porphyrias 
also serve as convenient model systems for studying the genetic hepatic 
porphyrias in man in as much as a number of the experimental porphyrias 
induced by drugs and chemicals resemble the different types of genetic 
porphyria (Table 1 .6) (228). 
It has been established that there are two main ways in which drugs 
and xenobiotics can be implicated in the derangement of liver porphyrin 
metaboiism: (1) They can induce a condition of hepatic porphyria in 
normal human individuals or in experimental animals in the absence of 
a genetic disposition to porphyria,or (2) they can precipitate an acute 
attack of hepatic porphyria in patients who are carriers of a genetic 
defect for acute porphyria in the latent state (220). Examples of the 
ability of chemicals to derange haem biosynthesis in these two ways will 
be discussed below (Sections 1 .8.1 - l .8.2). 
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TABLE 1.6 
EXPERIMENTALLY INDUCED PORPHYRIAS WHICH ARE USED AS MODEL SYSTEMS 
FOR STUDYING HUMAN PORPHYRIAS 
AGENT USED TO INDUCE PORPHYRIA 





U.V. light exposure 
AIA 
THE HUMAN PORPHYRIA FOR WHICH THE 
EXPERIMENTAL PORPHYRIA IS USED AS 
A MODEL SYSTEM 
Variegate Porphyria 
Variegate Porphyria 
Porphyria Cutanea Tarda 
Congenital Erythropoietic Porphyria 
Congenital Erythropoietic Porphyria 
Experi~ental Porphyria (does not 
resemble any specific human 
genetic porphyria) 
No chemical model of porphyria exactly replicates any of the genetic 
porphyrias but merely provides an approximate biochemical simulation 
of these conditions. 
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1.8.1. Chemically induced porphyria 
The first reported case of the ability of chemicals to induce a state 
of porphyria in experimental animals and man was in 1889, when Stokvis 
observed porphyric symptoms in patients with sulfonal poisoning (168, 
229). However, Stokvis could not be certain that these patients did 
not have a genetic defect of haem biosynthesis in the latent state (190). 
1.8.1.1. Hexachlorobenzene (HCB) (Fig. 1.17) 
The outbreak of porphyria in Turkey in 1956 was the first direct evidence 
for the occurrence of a purely acquired and not genetically predetermined 
form of hepatic porphyria in man (190). This outbreak was caused by 
ingestion of hexachlorobenzene-treated wheat by several genetically dis-
tinct population groups (230-232). Subsequent experiments with labora-
tory animals have shown that hexachlorobenzene produces a form of 
hepatic porphyria which closely resembles Porphyria Cutanea Tarda 
(Tables 1.5, 1.6) (233) in that the activity of uroporphyrinogen decarb-
oxylase is decreased (234). 
1.8.1.2. Dicarbethoxydihydrocollidine (DOC) (Fig. 1.17) 
DOC was used in 1959 by Solomon and Figge (235) to produce experimental 
porphyria. It has been established that DOC will induce a porphyria 
in experimental animals which closely resembles human hepatic Variegate 
Porphyria (Tables 1.5, 1.6) (228) in that the activity of the enzyme 
ferrochelatase is decreased, resulting in an increase in the excretion 
of protoporphyrin IX (236) and an increase in the levels of ALA-
synthetase (150). 
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Only very recently has the mechanism whereby DOC inhibits ferro-
chelatase been established. DOC treatment promotes the accumulation 
in the liver of a modified porphyrin with strong inhibitory activity 
towards ferrochelatase (237-239). The structure of this porphyrin 
has been determined to be N-methylprotoporphyrin IX (131, 240, 241) 
formed by covalent attachment of a methyl group from DOC to one of the 
pyrrole nitrogens of the porphyrin nucleus of liver haem (242). 
Contrary to earlier reports which suggested that no part of the DOC 
molecule was attached to the modified porphyrin (238), the methyl group 
of N-methylprotoporphyrin IX has now been shown conclusively to origin-
ate from the 4-methyl substituent of DOC (Fig. 1.17) (131, 240). All 
four isomers of N-methylprotoporphyrin IX are equally potent inhibitors 
of ferrochelatase (241); however, the nitrogen in pyrrole ring A of 
protoporphyrin IX appears to be preferentially alkylated by DOC in 
vivo (243). 
Since DOC does not inhibit ferrochelatase in vitro (236) and activation 
of DOC jy hepatic microsomal cytochrome P-450 is required for the 
formation of the modified porphyrin (242), it has been postulated that 
the 4-methyl substituent of DOC is eliminated during the cytochrome 
P-450 catalyzed oxidation of DOC (131). However, the exact mechanism 
of formation of N-methylprotoporphyrin IX is at present unknown. 
The manner in which the modified porphyrin inhibits ferrochelatase is 
thought to involve the binding of N-methylprotoporphyrin IX to the 
porphyrin binding site at the active site of the enzyme (238), thus 
interfering with the normal incorporation of Fe2+ into protoporphyrin 
and accounting for the accumulation of protoporphyrin IX and the in-
duction of porphyria in DOC treated animals (238). Since N-methyl-
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protoporphyrin IX is also present in the livers of untreated animals 
(240), it has been proposed that the endogenous presence of N-methyl-
protoporphyrin IX may be important in the regulation of haem bio-
synthesis (240). The source of the methyl group for endogenous 
N-methylprotoporphyrin IX is unknown at this time, but it may be 
possible that it is derived from endogenous metabolites similar in 
structure to DOC. On the other hand, there may be xenobiotics present 
in food or air which contribute to the production of endogenous N-methyl-
protoporphyrin IX (240). 
1.8.1.3. Allyl-i?..Q.-propylacetamide (AIA) (Fig. 1. 17) 
AIA was first used by Goldberg and Rimington in 1955. 
AIA is a chemical which is commonly used to induce experimental porphyria 
in animals. A single injection of AIA causes a striking increase in 
hepatic ALA-synthetase activity (215, 220) and a marked increase in the 
excretion of haem precursors in the urine and faeces of these animals 
(244). AIA is also known to cause a transient decrease in the levels 
of hepatic microsomal cytochrome P-450 which precedes the increase in 
ALA-synthetase activity (245, 246). The decrease in the levels of cyto-
chrome P-450 is due to the interaction of AIA with the haem moiety of 
cytochrome P-450. 
AIA degrades the haem moiety of hepatic microsomal cytochrome P-450 in a 
highly specific, suicidal process (121) which requires catalytically 
competent enzyme, NADPH and oxygen (127). The specificity of this 
process is attested to by the fact that AIA selectively destroys only 
the haem moiety of cytochrome P-450 whereas the apoprotein moiety 
appears to be unchanged (125, 126). Since AIA is primarily metabolized 
by and exclusively degrades the major phenobarbital-inducible form of 
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cytochrome P-450 (127, 132), it appears that a reactive metabolite of 
AIA, generated in situ, selectively destroys the haem moiety of this 
isoenzyme (121) before diffusing out of the active site (136). 
The product of the AIA mediated degradation of cytochrome P-450 is an 
abnormal green pigment which accumulates in the liver of AIA treated 
anim3ls and is not catabolized by haem oxygenase (248). Although the 
exact structure of the pigment has not been determined, it it thought 
to be an N-substituted porphyrin (137) which is formed by 1 :1 covalent 
attachment of a portion of the AIA molecule to protoporphyrin IX (249), 
the protoporphyrin IX being derived from the prosthetic haem moiety of 
inactivated cytochrome P-450 (249). This abnormal porphyrin differs 
from the N-substituted porphyrin formed by DOC treatment (Section 
1.8.1 .2) in the nature of the substituent on protoporphyrin IX (127, 
131, 238) and by the fact that it does not inhibit ferrochelatase (238). 
Since the AIA mediated degradation of cytochrome P-450 and the formation 
of the abnormal porphyrin result in the loss of haem from cytochrome 
P-450, the intact apoprotein which remains will draw haem from the 
central hep3tic haem pool for the reconstitution of the holoenzyme 
(230). Thus, after AIA treatment, the apoprotein of cytochrome P-450 
can be visualized as a catalytic centre for the degradation of newly 
synthesized endogenous haem (250) and in this way causes depletion of 
the hepatic regulatory haem pool, thereby decreasing the negative 
feedback control by haem on ALA-synthetase and resulting in the stimu-
lation of ALA-synthetase activity and the development of hepatic 
porphyria (220). 
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1.8.2. Chemical precipitation of an acute attack 
Many lipid-soluble drugs (Table 1.7) (255) can precipitate an acute 
attack of hepatic porphyria in patients who are carriers of a genetic 
defect in the latent state (220). Both in vivo and in vitro, 
barbiturates and many lipid-soluble drugs, alone, have relatively 
small inducing capacities for ALA-synthetase (228). These drugs are 
much more effective in stimulating hepatic ALA-synthetase if a partial 
block in liver haem biosynthesis has been established, such as in 
patients with a genetically determined defect of haem biosynthesis 
(Fig. 1. 16) (Table 1.5) or in experimental animals treated with DOC 
(251). These results suggest that the sensitivity of patients with 
genetic porphyria of an acute variety to barbiturates and other lipid-
soluble drugs may depend on the partial block in haem biosynthesis 
which already exists in their livers as a result of the genetic defect 
(252). This interpretation is supported by the finding that in tissue 
culture, inhibition ~haem biosynthesis by several agents, will poten-
tiate synergistically the induction of ALA-synthetase by drugs (253, 254). 
1.9. THE EFFECTS OF CARBON DISULPHIDE ON HEPATIC HAEM METABOLISM AND 
HEPATIC MICROSOMAL CYTOCHROME P-450 
In contrast to chemicals such as AIA and DOC which cause an increase 
in hepatic haem biosynthesis, carbon disulphide causes an increase in 
hepatic haem biodegradation (256) and a slight decrease in hepatic haem 
biosynthesis (256). However, the effects of carbon disulphide on 
hepatic haem metabolism are thought to be a consequence of the carbon 
disulphide mediated destruction of hepatic microsomal cytochrome P-450 
( 256). 
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TABLE 1. 7 














































































































































































TABLE 1.7. (contd.) 
Dangerous drugs Grading* Contentious drugs+ 




Hyoscine butyl bromide dipyrone A 
Sodium phenyl dimethyl pyrazolone A 
Metoc l oprami de B 









* A based on human 
..., 








reported by 3 
reported by l 
C based on experiments in animal models. 
Ethanol 
or more authors. 
or 2 authors. 
D based on experiments on chick embryo liver cell culture or in ovo. --
+ Contentious drugs are those drugs for which conflicting data are 
a.vailable (255). 
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The metabolism of carbon disulphide by cytochrome P-450 is thought 
to produce one or more reactive species of sulphur which can bind 
covalently to the apoprotein of cytochrome P-450 (256, 257). Con-
sequently, the affinity of the modified apoprotein for haem is reduced 
and carbon disulphide-modified cytochrome P-450 dissociates into haem 
plus modified apoprotein moieties (120, 256). The appearance of cyto-
chrome P-420 in the microsomes from carbon disulphide treated animals 
(258, 259) supports this theory since some of the haem which is lost 
from cytochrome P-450 presumably becomes bound to microsomal lipid, 
giving rise to the spectrum of cytochrome P-420 (Fig. 1. 10) (134). 
Thus, the carbon disulphide mediated dissociation of cytochrome P-450 
results in an increase of free haem in the liver and in the regulatory 
haem pool in the cytosol (a migration of radioactive haem from the 
microsomes to the cytosol has been observed after carbon disulphide 
treatment (256)). The increased levels of haem in the regulatory haem 
pool cause an increase in the activity of hepatic haem oxygenase (256) 
and a slight decrease in the activity of hepatic ALA-synthetase (256). 
These effects are in contrast to the effects observed after AIA treatment 
where a decrease in hepatic haem levels results in an increase in hepatic 
ALA.-synthetase (Section 1.8.1.3) (220,250). 
1 . 10. PURPOSE OF PROPOSED INVESTIGATIONS 
As shown in this Introduction, there are several ways in which chemicals 
can interfere with hepatic haem metabolism. The primary effects of these 
chemicals on haem metabolism appear to be classifiable as follows: 
(A) The compound can mediate the modification of the haem moiety of 
hepatic microsomal cytochrome P-450, resulting in a decrease in the 
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levels of haem in the regulatory haem pool and the subsequent 
stimulation of hepatic haem biosynthesis (cf. AIA (Section 1.8.1.3)). 
(B) The chemical may stimulate the dissociation of hepatic microsomal 
cytochrome P-450 into haem plus modified apoprotein, resulting 
in an increase of haem in the regulatory haem pool and thereby 
increase hepatic haem biodegradation (cf. carbon disulphide 
(Section 1. 9)). 
(C) Finally, a compound may inhibit one of the key enzymes of haem bio-
synthesis, resulting in a block in the haem biosynthetic pathway 
and a decrease in the negative feedback control of haem on ALA-
synthetase (cf. DOC (Section 1.8.1.2)). 
In this thesis, we have attempted to gain some further insight into 
the mechanism of control of haem metabolism and the production of experi-
mental porphyria by examining the role of hepatic microsomal cytochrome 
P-450 in controlling the pathways for the biosynthesis and biodegradation 
of haem. More specifically, the roles of the apoprotein and haem 
moieties of this enzyme in controlling haem metabolism were investigated 
a S fo 11 Oi·/3 : 
Firstly, two compounds which decrease the haem of cytochrome P-450, e.g. 
fluroxene and trichloroethylene, were utilized to determine the effects 
of the haem of this enzyme on the regulation of hepatic haem biosynthesis; 
and 
Secondly, one compound which apparently affects both the haem and apo-
protein moieties of cytochrome P-450, viz. halothane, was utilized to 
ascertain the play-off of these two effects on hepatic haem biosynthesis 
and haem biodegradation. 
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I I MATERIALS 
Fluroxene (2,2,2-trifluoroethyl vinyl ether) was obtained from Ohio 
Medical Products, Madison, Wisconsin, U.S.A. Halothane (2-bromo-2-
chloro-l ,l ,l-trifluoroethane) was from I.C.I. Ltd., Johannesburg, South 
Africa. Trichloroethylene and tetrachloroethylene were purchased 
from Merck Chemicals, Darmstadt, Germany. The inducing agents sodium 
phenobarbital and 3-methylcholanthrene were supplied by Maybaker Ltd., 
Port Elizabeth, South Africa and Eastman Kodak Company, Rochester, New 
York, U.S.A., respectively. NADPH, crystalline bovine serum albumin 
and the components of the NADPH-generating system (NADPH, glucose-6-
phosphate and glucose-6-phosphate dehydrogenase) were purchased from 
Miles Laboratories, Cape Town, South Africa. Haemin (haematin HCl) 
and BF3/methanol were obtained from British Drug Houses Ltd., Poole, 
Dorset, U.K. o-Aminolevulinic acid hydrochloride (ALA-HCl) and porpho-
bilinogen \vere supplied by Sigma Chemical Company, Saint Louis, Missouri, 
u. s. ,L\. Cyclohexanone and acetylacetone were obtained from Merck, Darm-
stadt, Germany. Afrox Limited, Caoe Town, South Africa, supplied cylin-
ders of pure gases. 2,2,2-Trifluoroethyl ethyl ether (TFEE) was pre-
pared by hydrogenation of fluroxene as described by Ivanetich et~- (135). 
[1.4- 14CJ-Succinic acid (50.7 mCi/mmole) was purchased from New England 
Nuclear, Boston, Massachusetts, U.S.A. Dicarbethoxydihydrocollidine 
(DDC) and resofurin were obtained from Eastman Kodak Company, Rochester, 
New York, U.S.A. Ethoxyresofurin was prepared from resofurin as des-
cribed by Burke and Mayer (260). Metyrapone [2-methyl-1 ,2-bis-(3-
pyridyl )-1-propaneJ was a gift from Ciba-Geigy Ltd., Bas le, Switzerland. 
Sephadex LH-20 was purchased from Pharmacia Fine Chemicals, Uppsala, 
Sweden. All other chemicals used were of the highest purity commer-
cially available. Water was glass distilled and deionized. 
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III METHODS 
3.1. EXPERIMENTAL ANIMALS 
Male Wistar rats weighing between 190 g and 210 g were used in all 
experiments, except where indicated. In the latter case, male Long 
Evans rats weighing between 190 g and 210 g were used. The animals 
were allowed free access to Epol Laboratory Chow (protein minimum 20%, 
fat 2.5\, fibre maximum 6%, calcium 1.4%, phosphorus 0.7%) unless other-
wise indicated and were allowed free access to water at all times. 
3.2. TREATMENT OF ANIMALS IN VIVO 
Cytochrome P-450 was induced by intraperitoneal injections of sodium 
phenobarbital (80 mg/kg/day in 0.9% saline for one day) or 3-methyl-
cho1anthrer.e (40 mg/kg/day in corn oil for three consecutive days). 
Animals which had been induced with sodium phenobarbital were adminis-
tered fluroxene, halothane or trichloroethylene at a dose of 1 ml/kg. 
Animals pretreated with 3-methylcholanthrene received 4 ml/kg of 
fluroxene. 
fluroxen2. 
Uninduced animals received either 4 ml/kg or 6 ml/kg of 
However, halothane or trichloroethylene was administered 
to uninduced animals at a dose of 2 ml/kg*.TFEE or tetrachloroethylene 
was injected into phenobarbital pretreated rats at a dose of l ml/kg. 
To both the 3-methylcholanthrene and phenobarbital pretreated animals, 
the compounds were administered 24 hours after the last injection of 
inducing agent. In the experiments where the anaesthetic agent was 
administered repeatedly, a dose of 1 ml/kg was administered to uninduced 
rats at 48 hour intervals. In all cases the compound was administered 
* These doses of the anaesthetic agents represent the maximum doses that 
could be administered to the Wistar rats without fatality. 
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neat by intraperitoneal injection. 
In one experiment, ALA-synthetase was induced by a single intraperi-
toneal injection of DOC (100 mg/kg in Arachis oil). Fluroxene was 
administered to these rats at a dose of 4 ml/kg ir11nediately after the 
DOC treatment. 
When the effects of halothane or fluroxene as a function of time were 
studied~ vivo, animals were starved 24 hours prior to fluroxene or halo-
thane treatment and sacrificed at 0, 1, 5 and 10 hours after halothane or 
fluroxene treatment or at equivalent times in controls. In all other 
cases, animals were starved 24 hours before being sacrificed by cervical 
fracture and, where required, the livers were removed immediately and 
used promptly. 
3.3. IN VITRO STUDIES 
For in vitro experiments rats were pretreated with sodium phenobarbital 
(80 mg/kg 1n 0.9% NaCl per day) for three consecutive days and fasted 
overnight prior to being sacrificed. Immediately upon sacrifice of 
the animals microsomes were prepared as described below (Section 3.4). 
Halothane (18 mM) or fluroxene (6 mM) was dispersed in microsomal sus-
pensions (2 mg protein/ml) by vortex mixing for 30 sec. NADPH-
generating system (65) and EDTA (0.2 mM) were added, and reaction 
mixtures were incubated at 30°C with shaking at 60 cycles/min. 
3.4. PREPARATION OF MICROSOMES 
Immediately after the animals were sacrificed, microsomes were prepared 
from fresh rat liver homogenates at 4°C by differential ultracentrifugation 
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according to the method of Holtzman and Carr (261 ). The microsomes 
were finally suspended at a concentration of 2 mg microsomal protein/ml 
in 0.02 M Tris-HCl, pH 7.4, and were used immediately after preparation 
(16). The protein concentration of the microsomal suspension, liver 
homogenate and post-mitochondrial supernatant was determined by the 
method of Lowry et~- (262) as modified by Chaykin (263), using bovine 
serum albumin as a standard. 
3.5. LIVER ASSAYS 
3.5.1. Microsomal assays 
3.5.1.1. Cytochrome P-450. 
The concentration of cytochrome P-450 in hepatic microsomes was deter-
mined from measurements of the difference spectra of carbon monoxide-
ferrocytochrome P-450 versus ferrocytochrome P-450, as described by 
Omura and Sato (264). An extinction coefficient of s = 91 mM- 1 was 
used for A450 nm - A490 nm 
3.5.1.2. Haem. 
The concentration of microsomal haem was determined by the reduced 
pyridine haemochromogen as described by Omura and Sato (264). An 
extinction coefficient of s = 34.7 mM-i was used for A557 nm - A575 nm' 
3.5.1.3. Metyrapone-ferrocytochrome P-450 complex. 
The concentration of the major phenobarbital-inducible form of cytochrome 
P-450 was determined in microsomes from phenobarbital treated rats from 
measurements of the difference spectra of metyrapone-ferrocytochrome P-450 
versus ferrocytochrome P-450 as described by Luu-The et~- (265), but cf. 
( 282). An extinction coefficient of s = 52 mM-l was used for 
A446 nm - A490 nm· 
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3.5. 1.4. Ethoxyresofurin deethylase activity. 
The concentration of the major 3-methylcholanthrene-inducible form of 
cytochrome P-450 was determined from the rate of 0-deethylation of 
ethoxyresofurin to resofurin, and monitored by recording the increase in 
fluorescence associated with the formation of resofurin as described 
by Burke and Mayer (260). ).excitation= 510 nm; ). ·. . = 586 nm em1ss1on 
3.5. 1.5. Haem oxygenase. 
The method described by Tenhunen et al. (204) was used with minor modi-
fications to determine the activity of hepatic haem oxygenase. The 
sample cuvette contained 18 000 g supernatant (approximately 5 mg 
protein), haemin* (17 wM), NADPH (0.6 mM), and potassium phosphate 
buffer, pH 7.4 (90 mM) in a total volume of 3 ml. In the reference 
cuvette NADPH was replaced by an equivalent volume of 0.1 M potassium 
phosphate buffer, pH 7.4. Enzyme activity was determined from the in-
crease in absorbance at 468 nm over 10 minutes at 37°C. The enzyme 




protein/ 10 min) 
== 





LA4h3 / 10 min= the change in absorbance at 468 nm over 10 minutes v nm 
s468 nm= 30 mM-
1 (204) 
vt = total volume in the reaction c~vette (3 ml) 
v-- = volume of supernatant used (ml) 
* A stock solution of haemin (1.0 mM) was prepared as follows: 10 mg 
haemin was dissolved in 5 ml 0.1 N NaOH containing 12 mg Tris and 
222 mg NaCl. To this solution was added 10 ml of 3% (w/v) bovine 
serum albumin, and the pH was adjusted to 7.4. 
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3.5.2. Uroporphyrinogen synthetase 
The activity of uroporphyrinogen synthetase in post-mitochondrial 
supernatant was determined from the loss of porphobilinogen as des-
cribed by Hutton and Gross (266). For spectrophotometric readings, 
the reaction mixtures obtained by the above method were diluted 1/15 
(v/v) with distilled H20. A volume of the diluted samples was mixed 
with an equal volume of modified Ehrlich's reagent (Section 3.7.1 ),and 
the absorbance at 553 nm was determined after 30 minutes in a Gilford 
single beam spectrophotometer. 
Enzyme activity was calculated from the amount of porphobilinogen 
which remained in the sample after 60 minutes reaction time, compared 
to the amount of porphobilinogen in the sample at zero time. 
Porphobilinogen remaining= 0 31 1 0.31 µmoles A60 (µmoles) · µmo es - AO x 553 nm 
553 nm 
0.31 µmoles= total µmoles of porphobilinogen added to the sample at 
zero time 
A0 553 nm= absorbance at 553 nm of sample at zero time 
A~~3 nm= absorbance at 553 nm of sample after 60 minutes 
3.5.3.1. ALA-synthetase. 
Rat liver homogenized in 3 volumes of 0.9% NaCl containing 0.5 mM EDTA 
and 10 mM Tris-HCl (pH 7.4) was used for the determination of ALA-
synthetase activity as described by Marver et~- (267,268). 0.5 ml 
of liver homogenate was incubated at 37°C for 30 minutes with 0.05 ml of 
0.08 mM ATP and 1.5 ml of a solution containing 200 µM glycine, 20 µM 
EDTA and 150 µM Tris-HCl (pH 7.2). On termination of the reaction with 
25% TCA, the ALA in the supernatant was converted to a pyrrole adduct by 
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condensation with acetylacetone. The pyrrole adduct was applied to a 
Dowex-1-acetate column (1x7 cm) equilibrated with 0.05 M sodium acetate 
pH 4.6. The column was washed with 10 ml of n-butanol containing 
0.01 M ammonium hydroxide and 10 ml of l M acetic acid. The ALA pyrrole 
was eluted with 10 ml of a mixture of glacial acetic acid and methanol 
(1:2). 
The eluate (ca. 8 ml) was reacted with an equal volume of modified 
Ehrlich's reagent (Section3.7.1) for 30 minutes, at which time the absorb-
ance at 556 nm was measured in a Gilford single beam spectrophotometer. 
One ml of a standard solution of ALA (8 µg/ml) was used (Section 3.7.1) 
to correct for losses sustained during the purification procedure. 
ALA-synthetase activity was calculated from the amount of ALA formed 
during the incubation as follows: 
Enzyme activity 
(µg ALA formed/mg 
protein/30 min) 
Aunknown 
556 nm 8 
VE 
unknown 1 
= -A-s t.,-a,---- x 3 x 
556 nm 
E X 
Vstd mg microsomal protein/ml 
Aunkno1vn 
556 nm = Absorbance at 556 nm of unknown 
Astd Absorbance at 556 nm of standard 556 = nm 
vE unknm•m = Volume of eluant of unknown 
E Volume of eluant of standard vstd = 
3.5.3.2. Assay for ALA-synthetase using radioisotopes. 
This assay was performed using radioactively labelled [1,4- 14c]-succinic 
acid according to the method described by Blekkenhorst (269). A known 
amount of [1 ,4- 14c]-succinic acid was incubated with rat liver homogenate 
and the amount of [14c]-ALA formed was used as a measure of the activity 
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of ALA-synthetase. This method was only used for the determination 
of ALA-synthetase activity in DOC treated rats. 
3.6. COLLECTION OF URINE AND FAECES 
Immediately after treatment with the compound or at an equivalent time 
in controls, animals were housed in groups of three in perspex metabolic 
cages for collection of urine and faeces. Animals were starved but 
allowed water ad libitum over the 24 hour collection period, after which 
time the animals were sacrificed immediately. In the experiments 
where the anaesthetic was administered repeatedly over a period of two 
to three weeks, the animals were allowed free access to food until 24 
hours before sacrifice and had free access to water throughout the 
experiment. For these experiments, the urine and faeces were collected 
over periods of 48 hours. 
maximum period of 7 days. 
Urine and faeces were stored frozen for a 
3.7. QUANTIFICATION OF HAEM PRECURSORS 
3.7.1. Estimation of urinary ALA and porphobilinogen 
The colorimetric method described by Mauzerall and Granick (193) was 
used for the quantitative determination of urinary ALA and porpho-
bilinogen. This method makes use of the retention of porphobilinogen 
and ALA on anionic and cationic ion exchange resins, respectively. 
Once eluted from their respective columns, ALA, in the pyrrole form, 
and porphobilinogen are determined colorimetrically with modified 
Ehrlich's reagent (l g .E_-dimethylaminobenzaldehyde and 8 ml 70% per-
chloric acid in 50 ml glacial acetic acid). The modified Ehrlich's 
reagent was allowed to react with porphobilinogen and ALA (in the 
75 
pyrrole form) for 15 minutes, after which time, the absorbance at 
555 nm and at 556 nm for porphobilinogen and ALA respectively, was 
measured immediately on a Gilford single beam spectrophotometer. 
In order to estimate the percentage recovery of ALA, 1 ml of a standard 
solution containing 8 µg of ALA was treated exactly as were the urinary 
samples and was subsequently analysed for ALA content. Reported values 
were thereby corrected for losses of ALA sustained during the purifica-
tion procedure. 
The equation given by Mauzerall and Granick (193) was used to determine 
urinary porphobilinogen levels: 
Urinary porphobilinogen (µg) = A555 nm x 0-328 x vt x Mr 
yo 
Vt= total volume of urine collected (ml) 
V0 = amount of urine placed on column (ml) 
A555 nm= absorbance at 555 nm 
Mr= molecular weight of porphobilinogen. 
The following equation was used to determine urinary ALA content: 
Urinary ALA (µg) = A556 nm unknown Vt X 8 µg/ml X 
A556 nm standard 
vi = total volume of urine collected (ml) 
A556 nm unknown= absorbance of unknown sample at 556 nm 
A556 nm standard= absorbance of standard sample at 556 nm. 
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3.7.2. Determination of urinary coproporphyrin and uroporphyrin 
3.7.2.1. Coproporphyrin. 
The method of Schwartz~~- (270) as modified by Holti et~- {271) 
was used with several minor modifications: 5 ml of urine was shaken 
with 0.5 ml of glacial acetic acid and 20 ml of diethyl ether. On 
separation of the two phases, coproporphyrin is found in the ether 
layer whereas uroporphyrin is retained in the aqueous layer. The 
aqueous layer was extracted with ether three or four times, and the 
ether extracts were combined for the determination of coproporphyrin. 
The combined ether extracts were washed once each with 20 ml of 0.5% 
sodium acetate, 20 ml of 0.005% iodine solutiori"and 10 ml of H20. The 
acetate, iodide and aqueous washes were combined with the initial 
glacial acetic acid-water layer and were set aside for the determination 
of uroporphyrin. 
The coproporphyrin was extracted repeatedly from the washed ether layer 
using 2 ml aliquots of 1.5 M HCl, until no further fluorescence was ob-
served in the extracts. The total volume of acid was recorded, and 
the solution was filtered when necessary. 
The coproporphyrin content was calculated from the absorbances at 380 nm, 
430 nm and at the Soret peak (ca. 405 nm). 
The correction formula of Rimington and Sveinsson{272) as modified by 
With (273), with an extinction coefficient given by Furhop and Smith 
(274) was used to determine urinary coproporphyrin levels. 
* Iodine solution is used to oxidise coproporphyrinogen to coproporphyrin. 
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Coproporphyrin (µg) =[2Amax - (A430 nm+ A380 nmU x 0· 728 
v1 
X - X 
Vo 
vt 
v1 = volume of HCl (ml) 
Vo = volume of urine used (ml) 
Vt = total volume of urine (ml) 
A = absorbance at Soret maximum max 
A430 = absorbance at 430 nm nm 
" = absorbance at 380 nm t-\380 nm 
3.7.2.2. Uroporphyrin. 
The method described by Dresel et~- (275) was used for the determination 
of urinary uroporphyrin. The combined aqueous washes from the copra-
porphyrin determination were extracted with cyclohexanone. To the cylco-
hexanone extracts, diethyl ether was added, and the uroporphyrin was ex-
tracted finally into 2% aqueous HCl. The uroporphyrin content of the 
HCl extracts was calculated from the absorbance of the Soret peak. 
The correction formula described by Rimington and Sveinsson (272) was 
used for determination of urinary uroporphyrin levels, with a slight 
modification to take into account the impurities present in the solutions. 
A tangent to the background slope was drawn, and the absorbance between 
the curve and the tangent at the Soret peak was subtracted from the total 
absorbance at the Soret peak (Amax) shown in Figure 3. 1. 
















1 indicates the corrected 
Amax value 
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At high concentrations of urinary uroporphyrin (ca. 6 µg) our results 
were consistent with results obtained using the Rimington and Sveinsson 
formula ( 272). However, at low concentrations of urinary uroporphyrin, 
below ca. 0.5 µg, our method of calculation proved to be more repro-
ducible. 
Uroporphyrin ( µg) = 2 [A ] X 0.855 
v2 Vt X - X max Vo 
v2 = volume of 2% HCl (ml) 
Vo = volume of urine used (ml) 
Vt = total volume of urine collected (ml ) 
A max = absorbance at Soret maximum (ca. 405 nm) 
3.7.3. Determination of coproporphyrin and protoporphyrin in faeces 
The method described by Holti et~- (271) was used for the determina-
tion of faecal coproporphyrin and protoporphyrin following minor modi-
fications: The combined ether extracts of the faeces were washed 
once each with 20 ml saturated sodium acetate, 20 ml 0.005% iodine 
solution and 20 ml H2o. The coproporphyrin was extracted from the 
ether phase into 0.1 M HCl, and the protoporphyrin was subsequently 
repeatedly extracted using 1.5 M HCl. The absorbance spectra of the 
coproporphyrin and protoporphyrin extracts were recorded over the range 
of 350 nm to 450 nm. 
Stool porphyrin content was reported per dry weight of faeces in all 
cases. The correction formulas described by Rimington and Sveinsson 
(272) as modified by With (273) were used for calculation of both the 
coproporphyrin and protoporphyrin content of the faeces. 
79 
Coproporphyrin (µg/g dry weight of faeces) 
v1 
= [2Amax - (A430 nm+ A380 nm)] x o. 73o x ~~~~ 
wet weight 
of faeces 
v1 = volume of 0.1 M HCl (ml) 
used 
Amax= absorbance at Soret maximum (ca. 405 nm) 
A = absorbance at 430 nm 430 nm 
A = absorbance at 380 nm 380 nm 
Protoporphyrin (µg/g dry weight of faeces) 
v2 
= [2Amax - (A430 nm+ A380 nm)] x l.OBO x ~~~~ 
wet weight 
of faeces 
v2 = volume of 1. 5 M HCl (ml) 
used 
Amax= absorbance at Soret maximum (ca. 408 nm) 
A = absorbance at 430 nm 430 nm 
A = absorbance at 380 nm 380 nm 











Administration of fluroxene to rat liver in vivo or in vitro results 
in the formation of a green pigment thought to be formed by attachment 
of fluroxene (or part thereof) to the prosthetic haem of cytochrome 
P-450 (132,276). 
3.8.1. Preparation in vitro and isolation 
The green pigment was prepared in vitro by incubation of fluroxene (6 mM) 
with hepatic microsomes from phenobarbital induced Wistar or Long Evans 
rats. EDTA and NADPH-generating system for 30 min, as described in 
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Section 3.3. At the end of the reaction period, excess fluroxene was 
removed by bubbling with nitrogen for 15 min at room temperature. 
The green pigment prepared as described above was isolated by a com-
bination of the methods described by McDonagh et~- (277) and Ortiz 
de Mantel lano et al. (278). The green pigment was extracted from --
hepatic microsomes (approximately 500 ml) with 3 volumes of ethyl 
acetate:acetic acid (4:1) (v/v). The extract was filtered, washed 
three times with aqueous saline (7.5% (w/v)) and evaporated to near 
dryness (~. 5 ml). A small volume of chloroform (1-3 ml) was added 
to the remaining brown oil. The chloroform solution was methylated 
with 10 ml of BF3/methanol (14% (w/v)) and the mixture was refluxed 
under nitrogen for 15 min. Upon cooling the reaction mixture, the 
methylated product was extracted into chloroform (80 ml) and washed 
twice with H2o (50 ml) and once with 1% (w/v) sodium bicarbonate (50 ml). 
After drying over sodium sulphate, the chloroform layer was reduced to 
1-2 ml by rotary evaporation. Purification of the methylated green 
pigment was performed using the following procedures:-
(1) HPLC - using a Whatman Partisil 10 PAC column eluted with tetra-
hydrofuran hexane : methanol (5:5:1 by volume) and then with 
methanol : tetrahydrofuran (4:1 (v/v)L and/or 
(2) TLC - using silica gel plates (20 cm x 20 cm : 0.2 mm thickness), 
developed in chloroform : kerosene : methanol (20:5:3 by volume)~ 
The developed plates were dried under a stream of cold air, the 
spots were located by their colour under a uv light, and the 
methylated product was extracted off the silica gel into chloroform: 
· methano 1 ( 1 : 1 ( v /v)). 
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The zinc complex of the methylated green pigment was prepared as 
described by Doss (279) and chromatographed using silica gel. The 
plates (20 cm x 20 cm: 0.2 mm thickness) were developed in 20% 
acetone/chloroform (v/v). The developed plates were treated as 
described above and the zinc complex was extracted off the silica 
gel into chloroform : methanol (1 :1 (v/v)). 
3.8.2. Preparation in vivo and isolation 
The green pigment was prepared..:!.!:: vivo using phenobarbital induced 
Wistar rats injected with fluroxene (2 ml/kg) as described in Section 
3.2 and killed l hour later. The method described by De Matteis et al. 
(238) was used to isolate the green pigment. 
The livers of 4 treated rats were pooled and homogenised in two volumes 
of 0.25 M sucrose. The homogenate (approx. 150 ml) was washed twice 
with an equal volume of acetone and centrifuged at 2000 rpm for 10 min. 
The pellet was extracted twice with 100 ml of acetone : HCl (120 : 0.2 
(v/v)) and centrifuged as described above. The extracts were combined, 
and the acetone was removed by rotary evaporation 3t 30°C. Two to three 
ml of H20 were added to the HCl extract. This caused precipitation of 
haem and protoporphyrin,which were removed by centrifugation at 2000 rpm 
for 10 min. The green supernatant was applied to a Sephadex LH-20 
column (20 x 1 cm) equilibrated with acetone : H20 (l :1 (v/v)). The 
green pigment was eluted with 10 ml of acetone : H20 (1 :1 (v/v)). 
All isolation steps were performed in the dark at room temperature. 
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3.9. SPECTROPHOTOMETRY 
Unless otherwise stated, a Beckman 5230 spectrophotometer or a Unicam 
SP 1800 spectrophotometer coupled to a Unicam AR 25 recorder was used 
for all spectral measurements. The compartment adjacent to the 
photonmultiplier was used whenever samples were particulate. 
3. 10. CALCULATIONS AND STATISTICAL ANALYSIS 
Results were given as means+ standard deviations and as percentages 
relative to control values. Where values were given in parentheses 
these represent results obtained on individual days. Determinations 
on each day were on the pooled livers, urine or faeces of three or 
more treated rats and three or more control rats. Assays were 
performed in duplicate to quadruplicate except for the determination 
of the urinary and faecal porphyrins, where sample size permitted 
single determinations only. In general, each result presented is an 
average of the determinations obtained on two or more days, the exception 
being for measurements of the levels of haem precursors in chronically 
treated animals where determinations were from a single day only. 
Statistical analysis of the data was usually performed using the 
Student's t-test for unpaired data. However, where day to day varia-
tion in results was lar-ge in comparison to the difference between rats 
treated with the anaesthetic and control rats on a given day, the Student's 
t-test for paired data was used to assess the statistical significance. 
Where the paired test was used for statistical analysis it has been 
noted in the tables. P values below 0.05 were regarded as indicating 
a probably significant difference between mean~ with P values below 
0.01 indicating a significant difference. 
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IV RESULTS 
4.1. ACUTE FLUROXENE TREATMENT 
4. 1.1. The effects of fluroxene on hepatic microsomal enzymes and haem 
in induced and uninduced rats 
4. 1.1.1. Cytochrome P-450 and haem 
The effects of fluroxene on the group of drug metabolizing enzymes known 
as cytochrome P-450 were determined using microsomes from uninduced and 
induced rats. Single injections of fluroxene into uninduced Wistar 
rats or Wistar rats previously induced with phenobarbital or 3-methyl-
cholanthrene, resulted in significant decreases in the levels of 
hepatic microsomal cytochrome P-450 (Table 4.1). As shown in Table 
4. 1, the extent of loss of cytochrome P-450 in the differently treated 
Wistar rats decreased in the following order: 
Phenobarbital induced> 3-methylcholanthrene induced 
~ uninduced (6 ml/kg) > uninduced (4 ml/kg). 
In all cases where fluroxene was administered to induced or uninduced 
rats, the losses of cytochrome P-450 per mg of microsomal protein 
were accompanied by similar losses of microsomal haem per mg of micro-
sornal protein (Table 4. 1). This is consistent with earlier reports, 
and appears to result from the ability of fluroxene to degrade the 
haem moiety of cytochrome P-450 ~ viv~ and~ vitr~ (132). Fluroxene 
(4 ml/kg) did not significantly affect the levels of microsomal cyto-
chrome P-450 or haem in Long-Evans rats in vivo (Table 4. 1). 
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4.1.1.2. Haem oxygenase 
The effect of fluroxene treatment in vivo on hepatic haem oxygenase 
was assayed in order to determine whether fluroxene had an effect 
on the physiological pathway for haem biodegradation. 
Significant increases in the activity of hepatic microsomal haem 
oxygenase were observed after fluroxene treatment of uninduced Wistar 
rats and Wistar rats previously induced with phenobarbital or 3-methyl-
cholanthrene (Table 4.2). In male Wistar rats the activity of haem 
oxygenase was increased in the following order: 
Uninduced (4 ml/kg)< 3-methylcholanthrene induced 
< uninduced (6 ml/kg) < phenobarbital induced. 
Furthermore, fluroxene significantly affected the activity of haem 
oxygenase in Long-Evans rats (Table 4.2). 
From the data presented in Table 4.2, it appears that there is a direct 
relationship between the loss of hepatic microsomal cytochrome P-450 
and haem and the percentage increase in the activity of hepatic haem 
oxygenase following fluroxene treatment. 
To determine whether haem oxygenase induction might be a consequence 
of the degradation of the haem of cytochrome P-450 by fluroxene, the 
activity of hepatic haem oxygenase and the levels of cytochrome P-450 
were measured as a function of time in phenobarbital induced rats 
(Table 4.3). In as much as the degradation of cytochrome P-450 was 
observed 1 hour after fluroxene treatment, whereas the activity of haem 
oxygenase was not elevated at 1 hour but only at 5 hours after fluroxene 
treatment, it was evident that cytochrome P-450 degradation preceded the 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1.2. The effects of fluroxene on the haem biosynthetic pathway 
in induced and uninduced rats 
4. 1.2.1. Urinary and faecal haem precursors 
The effects of fluroxene on the haem biosynthetic pathway were assessed 
by measuring the amounts of haem precursors excreted in the urine and 
faeces after fluroxene treatment of uninduced Long Evans and Wistar 
rats and Wistar rats previously induced with phenobarbital or 3-methyl-
cho·I anthrene. 
A single injection of fluroxereinto uninduced Wistar rats did not 
affect or resulted in a slight increase in the levels of ALA (Table 4.4). 
Significantly increased amounts of urinary ALA did, however, follow 
fluroxene treatment of 3-methylcholanthrene and phenobarbital induced 
rats. Porphobilinogen was significantly elevated by fluroxene treat-
ment of uninduced and induced Wistar rats (Table 4.4). No significant 
changes in urinary and faecal porphyrin levels were observed after 
fluroxene treatment of Wistar rats (Tables4.5 and 4.6). 
Fluroxene treatment of uninduced male Long Evans rats did not result 
in significant increases in the levels of haem precursors in urine 
and faeces, except for a significant increase in the amount of ALA 
(Tables 4.4 - 4.6). 
4. 1.2.2. Hepatic ALA-synthetase 
Since significantly increased levels of the urinary haem precursors 
porphobilinogen,and in some cases ALA,were observed followinq fluroxene 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































on the activity of the rate-limiting enzyme of the hepatic haem bio-
synthetic pathway, ALA-synthetase, was measured (Table 4.7). 
Both uninduced and induced Wistar rats exhibited significant increases 
in the activity of ALA-synthetase after fluroxene treatment. The most 
striking effect on the activity of ALA-synthetase was obtained with 
3-methylcholanthrene induced rats. 
4.2. 2,2,2-TRIFLUOROETHYL ETHYL ETHER (TFEE) TREATMENT 
4.2. 1. The effects of TFEE on hepatic microsomal enzymes in pheno-
barbital induced rats 
The effects of a single injection of TFEE on hepatic microsomal enzymes 
were assessed in phenobarbital induced male Wistar rats (Table 4.8). 
As found earlier for TFEE anaesthesia (72,135), an injection of TFEE 
into phenobarbital induced rats did not result in the degradation of 
hepatic microsomal cytochrome P-450 or haem. Furthermore, TFEE did 
not alter the activity of hepatic microsomal haem oxygenase (Table 4.8). 
4.2.2. The effects of TFEE on the levels of urinary and faecal haem 
precursors in phenobarbital induced rats 
A single injection of TFEE into phenobarbital induced Wistar rats 
caused no significant alteration in the levels of the urinary or 
faecal haem precursors; i.e. no alteration in the levels of ALA, 




THE EFFECTS OF FLUROXENE ON THE ACTIVITY OF HEPATIC ALA-SYNTHETASE 
IN INDUCED AND UNINDUCED WISTAR RATS 
Rats were sacrificed 16 hours after fluroxene treatment or at an 
equivalent time in control animals. Results are means+ S.D. for 
assays performed in triplicate on each of three or more separate 
groups of three animals. 
INDUCTION DOSAGE OF ALA-SYNTHETASE 
FLU ROX ENE µg ALA formed/mg % Relative to 
ml/kg protein/30 min controls 
NONE None 0.024 ± 0.005 
4.0 0.038 ± 0.006+ 158 
NONE None 0.023 ± 0.004 
6.0 0.035 ± 0.010* 152 
MC None 0.021 ± 0.004 
4.0 0.052 ± 0.003+ 248 
PB None 0.036 ± 0.004 
1.0 0.047 ± 0.010* 131 
Abbreviations: ALA, 6-aminolevulinic acid; MC, 3-methylcholanthrene; 
PB, phenobaribtal. 
* Differs significantly from identically induced rats not treated with 
fluroxene, P < 0.01. 
+ Differ3 significantly from identically induced rats not treated with 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3. CHRONIC FLUROXENE TREATMENT 
4.3.1. The effects of fluroxene on hepatic microsomal enzymes and 
haem in uninduced rats 
Uninduced Wistar rats were given repeated fluroxene treatment for a 
period of 22 days, the last injection being given 16 hours before 
sacrifice. Control values were taken from untreated rats kept under 
similar conditions for 22 days (Experimental details are given in 
Table 4.10). 
The levels of cytochrome P-450 were unchanged relative to control 
values, as were the levels of hepatic microsomal haem, after chronic 
fluroxene treatment. In addition, the activity of hepatic haem 
oxygenase was unaffected after chronic fluroxene treatment (Table 4.10). 
4.3.2. The effects of chronic fluroxene treatment on the hepatic haem 
biosynthetic pathway in uninduced rats 
4.3.2.1. Urinary and faecal haem precursors 
The results of two separate experiments showing the effects of chronic 
fluroxene treatment on the levels of urinary and faecal haem precursors 
are re?orted in Tables 4. 11 - 4.16. In both experiments, day l -
where no f1uroxene had as yet been administered to the rats - was treated 
as the control. Identical control values were obtained with respect to 
levels of haem precursors, from rats given no fluroxene but kept under the 
same conditions as the experimental rats for the duration of the experi-
ment (data not shown). The results from each experiment represent 


























































































































































































































































































































































































































































































































Experiment l was performed over a period of 16 days (7 injections of 
fluroxene) and experiment 2 was continued for a total of 22 days (10 
injections of fluroxene). 
In both experiments, the levels of urinary ALA were generally increased 
following chronic fluroxene treatment, but a dose-response relation-
ship was not evident (Table 4.11). Urinary porphobilinogen levels 
generally increased with an increasing number of injections of fluroxene 
over the experimental period. Extremely high levels of porphobilinogen 
were found in the urine of experimental animals towards the end of both 
experiments 1 and 2 (Table 4.12); increases corresponding to~- 2000% 
of the levels of porphobilinogen in the urine of control rats were 
observed. 
Urinary uroporphyrin levels were initially increased in both experi-
ments but gradually decreased in experiment 2 until the levels were 
equivalent to the control value or below (Table 4.13). Coproporphyrin 
levels in the urine were slightly increased after one fluroxene injec-
tion and remained elevated throughout the experiments (Table 4.14). 
The faeces of the rats studied showed slightly decreased levels of both 
coproporphyrin and protoporphyrin relative to day 1 of the experiments 
(Tables 4. 15 and 4. 16). 
4.3.2.2. Hepatic ALA-synthetase 
The activity of the rate-limiting enzyme of haem biosynthesis, ALA-
synthetase, was significantly elevated after chronic treatment of rats 
with fluroxene for a period of 22 days (Table 4.17). Control values 
were measured using untreated rats kept under similar conditions for 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































THE EFFECTS OF CHRONIC FLUROXENE TREATMENT ON THE LEVELS OF FAECAL 
COPROPORPHYRIN IN UNINDUCED RATS 
Uninduced rats were injected with fluroxene (1.0 ml/kg) every 48 hours. 
Faeces was collected from groups of three rats over a period of 48 hours, 
commen:ing immediately after each injection of fluroxene. 
Day l - where no fluroxene had as yet been administered to the rats -
was treated as the control. Results are single determinations on 
each separate group of three rats. The S.D. value for duplicate deter-
minations on one sample is 4.0. 
DAY NO. OF COPROPORPHYRIN 
FLUROXENE EXPERIMENT 1 EXPERIMENT 2 iNJtCTIONS 
µg/g dry % Relative µg/g dry % Relative 
wt. to controls wt. to controls 
/3 rats /3 rats 
0 21.6 100 14.7 100 
3 9.0 42 10.8 73 
5 2 12.3 84 
7 3 14.4 98 
9 4 10 .5 71 
11 5 11. 7 80 
13 6 10. 5 71 
15 7 13.2 61 
17 8 8.7 59 
19 9 6.9 47 
21 10 7.8 53 
Abbreviation: wt. ~ we i g ht. 
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TABLE 4.16 
THE EFFECTS OF CHRONIC FLUROXENE TREATMENT ON THE LEVELS OF FAECAL 
PROTOPORPHYRIN IN UNINDUCED RATS 
Details as in Table 4.15. Results are single determinations on each 
group of three rats. The S.D. value for duplicate determinations on 
one sample is 8.5. 
DAY NO. OF PROTOPORPHYRIN 
FLUROXENE EXPERIMENT 1 EXPERIMENT 2 INJECTIONS 
µg/g dry % Relative µg/g dry % Relative 
wt. to controls wt. to controls 
/3 rats /3 rats 
1 0 53. 1 100 41. 7 100 
3 1 24.3 46 36.9 88 
5 2 41. 1 99 
7 3 50.7 122 
9 4 31.8 76 
11 5 36.6 88 
13 6 34.2 82 
15 7 38.7 73 
17 8 40.2 96 
19 9 31.8 76 
21 10 31.8 76 
Abbreviation: wt., weight. 
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TABLE 4.17 
THE EFFECTS OF CHRONIC FLUROXENE TREATMENT ON THE ACTIVITIES OF HEPATIC 
ALA-SYNTHETASE AND UROPORPHYRINOGEN SYNTHETASE IN UNINDUCED RATS 
Animals were injected with fluroxene at a dose of l ml/kg every 48 hours 
for a period of 22 days (10 injections of fluroxene). Rats were sacri-
ficed on day 23, 16 hours after the final fluroxene injection, or at an 
equivalent time in control animals. Control values were taken from 
untreated rats kept under identical conditions for the duration of the 
experiment. Results are means+ S.D. for determinations in triplicate 
on each of two or more groups of three rats. 
FLUROXENE ALA-SYNTHETASE UROPORPHYRINOGEN SYNTHETASE 
ml/kg µg ALA formed % Relative µg PBG used % Relative 
/mg protein to controls /mg protein to controls 
/30 min /60 min 
None 0.021±0.003 2.95±0.35 
1. 0 0.042±0.002+ 200 1.35±0.07* 46 
Abbreviations: PBG, porphobilinogen; ALA, o-aminolevulinic acid. 
* Differs significantly from identically treated rats not receiving 
fluroxene, P < 0.01. 
+ Differs significantly from identically treated rats not receiving 
fluroxene, P < 0.001. 
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4.3.2.3. Hepatic uroporphyrinogen synthetase 
Since the levels of porphobilinogen, and to a lesser extent ALA levels, 
were elevated in the urines of uninduced rats after chronic fluroxene 
treatment, the activity of hepatic uroporphyrinogen synthetase, the 
enzyme which catalyzes the formation of uroporphyrinogen from porpho-
bilinogen (Fig. 1.11) was determined in rats after chronic fluroxene 
treatment for a period of 22 days. The activity of uroporphyrinogen 
synthetase in these animals was approximately 50% of that found in 
control animals (Table 4.17). 
4.4. FLUROXENE TREATMENT OF DOC TREATED RATS 
4.4. 1. The effect of fluroxene on the activity of hepatic ALA-
synthetase in DOC treated rats 
DOC (100 mg/kg in oil) and fluroxene (4 ml/kg) were injected into a 
group of Wistar rats, with the control animals receiving DOC alone. 
In these animals, hepatic ALA-synthetase activity was determined using 
a sensitive isotopic assay (269) capable of detecting small changes in 
the activity of ALA-synthetase. The activity of ALA-synthetase was 
found to be slightly (and probably significantly) increased in 
fluroxene treated rats relative to the control animals (Table 4.18). 
4.5. CHARACTERIZATION OF THE GREEN PIGMENT 
When the livers of rats were treated with fluroxene in vivo or in vitro, 
a green pigment (or haem adduct) collected in the microsomal fraction 
of the liver (132). Isolation and purification of the green pigment 
using HPLC or Sephadex LH-20 chromatography, as described in Section 3.8, 
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TABLE 4.18 
THE EFFECT OF FLUROXENE TREATMENT ON THE ACTIVITY OF HEPATIC 
ALA-SYNTHETASE IN DOC TREATED RATS 
Rats were sacrificed 16 hours after fluroxene treatment or at an 
equivalent time in control animals. Results are means+ S.D. for 






µmoles ALA formed/g wet wt. 
of liver/60 min 
1.9 ± 0.4 
2.6 ± 0.3* 
% Relative to controls 
137 
Abbreviations: ALA, o-aminolevulinic acid; DOC, dicarbethoxydihydro-
collidine; wt., v1eight. 
* Probably differs from identically induced rats not treated with 
fluroxene, P < 0.05. 
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gave rise to three distinct fractions of material with absorbance 
maxima around 400 nm: a brown fraction containing haem, a fraction 
with a typical porphyrin spectrum containing protoporphyrin IX and 
a green fraction containing the adduct. The green pigment was 
found to be distinct from both protoporphyrin IX and haem when 
analyzed by absorption spectroscopy (Figs. 4.1, 4.2). Further-
more, when chromatographed on TLC plates (Section 3.8.l), the green 
pigment was clearly separable from both the haem and protoporphyrin 
IX fractions - approximate Rf values are: green pigment methyl ester, 
0.21; haem methyl ester, 0.36; protoporphyrin IX methyl ester, 0.80. 
The scarlet-red fluorescence of the green pigment under U.V. light 
and the characteristics of its absorption spectrum indicated that the 
green pigment was a porphyrin derivative. A neutral aetio-type 
porphyrin spectrum was obtained after isolation and methylation of 
the adduct generated~ vitro (Fig. 4.1). When the adduct was 
isolated using Sephadex LH-20 chromatography (Section 3.8.2), the 
green fraction showed a typical porphyrin dication spectrum (peaks 
at 416 nm~ 562 nm, 608 nm) (238). 
In the absorption spectrum of the adduct at neutrality, the absorbance 
maxima were shifted towards the red compared with those of protopor-
phyrin IX (Figa 4.1); the observed shifts were very similar to those 
previously reported for N-methyl octaethyl porphyrin and for other 
N-substituted green oigments (131, 280). Furthermore, the zinc 
complex of the methylated adduct showed an unusual bathochromic shift 
of the Soret band from 413 nm to 430 nm (zinc complex) (Fiq. 4.1). 
This has previously been demonstrated for N-methylated octaethyl-







































































































































































































































































































































































































































































































































































































































































































(The substituent on the pyrrole nitrogen results in steric strain on 
the molecule and probable incomplete co-ordination of the metal) 
( 237) . 
The above facts indicated that the green pigment was an N-substituted 
porphyri n. 
Further characterization of the adduct required mass spectroscopy and 
nuclear magnetic resonance using highly sophisticated equipment to 
which I had no access. Attempts to transport the isolated adduct to 
San Francisco, USA, for further characterization failed due to the 
instability of the adduct (281). 
Kunze et~- (138), using field desorption mass spectroscopy and 
360 mHz NMR spectroscopy, confirmed that the adduct is an N-substituted 
porphyrin - the exact structure of the adduct being N-(2-axoethyl)proto-
porphyrin IX. 
4.6. THE ACTIVITY OF HEPATIC UROPORPHYRINOGEN SYNTHETASE IN VITRO 
4.6.1. The effects of fluroxene and its metabolites on the activity 
of hepatic uroporphyrinogen synthetase in vitro 
The activity of hepatic uroporphyrinogen synthetase was inhibited by 50% 
after chronic fluroxene treatment_:!!!_ vivo (Table 4.17). In order to 
determi.ne whether fluroxene or its metabolites viz. 2,2,2-trifluoroethanol, 
trifluoroacetic acid and trifluoroacetaldehyde were responsible for the 
observed decrease in the activity of uroporphyrinogen synthetase, the 
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effects of these compounds on the activity of hepatic uroporphyrinogen 
synthetase were determined~ vitro (details are given in Table 4.19). 
As shown in Table 4.19, neither fluroxene nor its metabolites had 
any significant effect on the activity of uroporphyrinogen synthetase 
in vitro. 
4.6.2. The effect of the green pigment on the activity of uropor-
phyrinogen synthetase in vitro 
Since fluroxene and its metabolites caused no significant change in 
the activity of uroporphyrinogen synthetase ~ vitro (Table 4.19), the 
effect of the green pigment on the activity of uroporphyrinogen 
synthetase was determined J..!:!_ vitro (Table 4.20). The green pigment 
was isolated in acetone : HCl (120 : 0.1 (v/v)), and neutralized with 
10 M KOH; therefore acetone, acetone HCl (120:0.1 (v/v) (neutralized)) 
and 3M KCl were utilized as controls. From Table 4.20 it is evident 
that the green pigment had no significant effect on the activity of 
hepatic uroporphyrinogen synthetase ~ vitro under the conditions or 
our experiments. 
4.7. ACUTE HALOTHANE TREATMENT IN VIVO 
4.7.1. The effects of halothane on hepatic microsomal enzymes and haem 
in induced and uninduced rats 24 hours after acute halothane 
treatment 
4.7.1.1. Cytochrome P-450 and haem. 
The effect of a single injection of halothane on the levels of hepatic 
cytochrome P-450 and haem in Wistar rats treated or not with phenobarbital 
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TABLE 4.19 
THE EFFECTS OF FLUROXENE AND ITS METABOLITES ON THE ACTIVITY OF 
UROPORPHYRINOGEN SYNTHETASE IN VITRO 
Uroporphyrinogen synthetase in post-mitochondrial supernatant from 
untreated rats (Section 3.5.2) was incubated with PBG (0.05 µmoles) 
and additions as indicated below, at 37°C for 60 min. The activity of 
uroporphyrinogen synthetase was determined as described in Section 
3.5.2. The standard reaction mixture contained post-mitochondrial 
supernatant and PBG (0.05 µmoles) (266). 
ADDITIONS UROPORPHYRINOGEN SYNTHETASE ACTIVITY 
(0.5 mM final cone.) µg PBG used/mg protein % Relative to 
/60 min standard 
None 0.013±0.003 100 
Fluroxene 0.015±0.001 115 
2,2,2-Trifluoroethanol 0.012±0.003 92 
Trifluoroacetic Acid 0.012±0.003 92 
Trifluoroacetaldehyde 0.015±0.003 115 
Abbreviations: PBG, porphobilinogen4 cone., concentration. 
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TABLE 4.20 
THE EFFECTS OF THE GREEN PIGMENT ON THE ACTIVITY OF UROPORPHYRINOGEN 
SYNTHETASE IN VITRO 
The green pigment was isolated in acetone:HCl (120:0.1 (v/v)) and purified 
using Sephadex LH-20 chromatography as described in Section 3.8.2. Acetone: 
HCl (120:0. 1 (v/v)) and the purified green pigment were neutralized 
with 10 M KOH prior to their incubation with uroporphyrinogen synthetase. 
Uroporphyrinogen synthetase in post-mitochondrial supernatant from un-
treated rats (Section 3.5.2) was incubated with PBG (0.05 µmoles) 
and the neutralized green pigment or controls as indicated below. The 
activity of uroporphyrinogen synthetase was calculated as described in 
Section 3.5.2. The standard reaction mixture contained post-mito-
chondrial supernatant and PBG (0.05 µmoles) (266). 
ADDITIONS UROPORPHYRINOGEN SYNTHETASE ACTIVITY 
100 1-1 l µg PBG used/mg protein OI lo Relative to 
/60 min standard 
None 0.014±0.003 100 
Acetone 0.015±0.001 107 
Acetone/HCl (120:0.1 (v/v)) 0.018±0.003 129· 
KCl {3 M) 0.016±0.001 114 
Green pigment 0.017±0.004 121 
Abbreviation: PBG, porphobilinogen. 
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is shown in Table 4.21. The levels of cytochrome P-450 were signifi-
cantly decreased in both phenobarbital induced and uninduced rats 24 
hours after halothane treatment. Although the losses of cytochrome 
P-450 in nmol/mg of microsomal protein were greater in phenobarbital 
induced rats than in rats not pretreated with this inducing agent, the 
percentage loss of cytochrome P-450 following halothane treatment was 
identical in phenobarbital induced and uninduced rats. Although the 
losses of cytochrome P-450 were accompanied by similar losses of micro-
somal haem (per mg of microsomal protein) (P > 0.05) in both untreated 
and phenobarbital pretreated rats, small but variable amounts of cyto-
chrome P-420 were observed in the microsomes of uninduced and pheno-
barbital induced rats after halothane treatment in vivo (Table 4.21) 
(See also Tables 4.24, 4.25). 
4.7.1.2. Haem oxygenase. 
Significant increases in the activity of hepatic haem oxygenase were 
obse~ved 24 hours after halothane treatment of uninduced and pheno-
barbital induced rats; the effect of halothane on haem oxygenase 
activity was more striking in uninduced than in phenobarbital induced 
rats (Table 4.21). 
4.7.2. The effects of halothane on hepatic haem biosynthesis in 
induced and uninduced rats after acute halothane treatment 
The Qffect of acute halothane treatment in vivo on hepatic haem bio-
synthesis was assessed by determining its effects on the activity of 
hepatic AlA-synthetase and on the levels of urinary haem precursors. 
When assayed 24 hours after acute halothane treatment, no significant 
































































































































































































































































































































































































































































































































































































phenobarbital induced or uninduced rats (Table 4.22). 
In uninduced rats acute halothane treatment resulted in a significant 
increase in the levels of urinary ALA and porphobilinogen (Table 4.23) 
but did not alter the levels of the urinary porphyrins (Table 4.23). 
Furthermore, acute halothane treatment did not affect the levels of 
any of the urinary haem precursors in phenobarbital induced rats over 
the 24 hour collection period (Table 4.23). 
4.7.3. The effects of acute halothane treatment on hepatic enzymes 
and haem as a function of time in phenobarbital induced 
rats in vivo 
4.7.3.1. Cytochrome P-450 and haem. 
In these experiments phenobarbital induced rats were injected with halo-
thane at time zero and sacrificed at 1, 5 and 10 hours after halothane 
treatment. Phenobarbital induced rats which did not receive halothane 
were utilized as the controls, and were sacrificed at times corresponding 
to 0, 5 and 10 hours after halothane treatment. 
One hour after the acute halothane treatment of phenobarbital induced 
rats, a significant decrease in the levels of microsomal cytochrome 
P-450 and haem were observed (Table 4.24). The losses of cytochrome 
P-450 and haem were maintained at both 5 and 10 hours after halothane 
treatment (relative to each corresponding set of controls). Generally 
at each time assayed the extent of loss of hepatic microsomal cytochrome 
P-450 was equivalent to the extent of loss of hepatic microsomal haem 
(P > 0.05) (Table 4.24). 
Acute halothane treatment was found to result in the production of 
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TABLE 4.22 
THE EFFECTS OF HALOTHANE IN VIVO ON THE ACTIVITY OF HEPATIC 
ALA-SYNTHETASE IN PHENOBARBITAL INDUCED AND UNINDUCED RATS 
Rats were sacrificed 24 hours after halothane treatment or at an equi-
valent time in control animals. Results are means.:!:. S.D. for assays 
performed in triplicate on each of three or more separate groups of 
three animals. 
INDUCTION DOSAGE OF ALA-SYNTHETASE 
R;ll;COTHJl;NE µg ALA formed/mg % Relative to 
ml/kg protein/30 min controls 
NONE None 0.017 + 0.003 
2.0 0.013 + 0.006 76 
PB None 0.014 + 0.006 -
1.0 0.015 + 0.005 107 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































hepatic microsomal cytochrome P-420 in vivo (Tables 4.21, 4.24, 4.25). 
In order to obtain an estimate of the amount of cytochrome P-420 
produced (in arbitrary units) at each time point studied (Table 4.25), 
the method of calculation described in Fig. 4.3 was utilized. A 
significant increase in theproduction of cytochrome P-420 was observed 
at 5 hours and 10 hours after acute halothane treatment in vivo, rela-
- --
tive to the corresponding control (Table 4.25). However, at these 
time points (viz. at 5 and 10 hours after halothane treatment) the 
loss of hepatic microsomal haem was equivalent to the loss of hepatic 
microsomal cytochrome P-450 (P < 0.05) (Table 4.24). Therefore, it 
was presumed that the amount of cytochrome P-420 produced after acute 
halothane treatment in vivo was too small to cause a significant differ-
ence between the losses of cytochrome P-450 and haem. 
4.7.3.2. Haem oxygenase. 
The activity of hepatic haem oxygenase was significantly increased at 
1, 5 and 10 hours after acute halothane treatment (relative to each 
corresponding set of control animals) (Table 4.26). At 5 hours after 
acute halothane treatment, the activity of hepatic haem oxygenase was 
significantly increased relative to its activity l hour after acute 
halothane treatment (P < 0.01). No further s~gnificant increase in 
haem oxygenase activity was observed between 5 hours and 10 hours 
after acute halothane treatment (P > 0.1). 
4.7.3.3. ALA-synthetase. 
The effect of acute halothane treatment as a function of time on the 
activity of ALA-synthetase 1n phenobarbital induced rats was most 
striking. One hour after acute halothane treatment, the activity of 
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TABLE 4.25 
THE EFFECTS OF HALOTHANE IN VIVO ON THE PRODUCTION OF CYTOCHROME 
P-420 AS A FUNCTION OF TIME IN PHENOBARBITAL INDUCED RATS 
Details as in Table 4.24. Results are means for determinations in 
triplicate on each separate group of three animals. Individual values 
were calculated as described in Fig. 4.3. 
HOURS AFTER DOSAGE OF CYTOCHROME P-420 




0 0 0.042 0.064 0.053 
+.014 
1.0 0.068 0. 077 0.073 0.020 
±_.011 
5 0 0.049 0.040 0.045 
.±, 008 
5 1. 0 0.100 0.120 0. 110 0.065* 
.±.021 
10 0 0.041 0.030 0.036 
+.013 
-
10 1.0 0.056 0. 102 0.079 0.043+ 
+.028 
-
*tA = Absorbance units, calculated as described in Fig. 4.3. 
+ Probably differs from identically treated rats not receiving halothane, 
P < 0.05. 
* Differs significantly from identically treated rats not receiving halothane, 












FIGURE 4 .3 
THE EFFECT OF HALOTHANE TREATMENT ON THE PRODUCTION OF CYTOCHROME 
P-420 IN VIVO AND THE METHOD OF CALCULATION OF THE ABSORBANCE DUE 
TO CYTOCHROME P-420 
Method of calculation of cytochrome P-420: 
A tangent to the slope was drawn and the difference between the absorb-
ance at 420 nm and the tangent was used to obtain values of 6A. 















































450 Wavelength (nm) 490 
- Absorbance spectrum of mi crosomes from phenobarbita 1 induced rats 
treated with halothane at time zero and killed 5 hours thereafter. 
-~-Absorbance spectrum of microsomes from phenobarbital induced rats 































































































































































































































































































































































































































































































































































































































































































hepatic ALA-synthetase was significantly increased relative to controls. 
However, the activity of ALA-synthetase returned to control levels 5 
hours after halothane treatment and was significantly decreased rela-
tive to controls at 10 hours (Table 4.26). Furthermore, the activity 
of ALA-synthetase returned to control levels 24 hours after halothane 
treatment (Table 4.22). 
4.8. CHRONIC HALOTHANE TREATMENT IN VIVO 
4.8. 1. The effects of chronic halothane treatment on hepatic micro-
somal enzymes and haem in uninduced rats 
These results were obtained from uninduced Wistar rats given repeated 
halothane injections every 48 hours. The rats were sacrificed 3 hours 
after the second and sixth injections of halothane. Day 1 - where no 
halothane had as yet been administered to the rats - was treated as the 
control. 
The levels of hepatic microsomal cytochrome P-450 and haem were signi-
ficantly decreased after the second and sixth injections of halothane. 
Furthermore, the extent of loss of hepatic microsomal haem corresponded 
to the extent of loss of hepatic microsomal cytochrome P-450 (Table 
4.27). 
The activity of hepatic haem oxygenase was strikingly elevated after 
the second injection of halothane but decreased to control values 

























































































































































































































































































































































































































































































































































































4.8.2. The effects of chronic halothane treatment on the hepatic 
haem biosynthetic pathway in uninduced rats 
4.8.2.l. Urinary haem precursors. 
The results of two experiments showing the effects of chronic halothane 
treatment on the levels of urinary haem precursors are reported in 
Tables 4.28 - 4.31. Uninduced rats were injected with halothane 
(1.0 ml/kg) every 48 hours and urine was collected from groups of three 
identically treated rats over a period of 48 hours, commencing immedi-
ately after each halothane injection. Experiments were performed 
over a period of 22 days (10 injections of halothane). Urine samples 
were assayed after every second halothane injection. Day 1 - where 
no halothane had as yet been administered to the rats - was the control 
for each experiment. 
Initially, the levels of urinary ALA and porphobilinogen were signifi-
cantly increased following 2 and 4 injections of halothane, but returned 
to control levels after the sixth injection of halothane. After the 
tenth injection of halothane the levels of ALA and porphobilinogen were 
again significantly increased relative to controls (Tables 4.28 and 
4.29). The levels of urinary uroporphyrin and coproporphyrin were 
significantly increased relative to controls after the second injection 
of halothane but subsequently the levels returned to those equivalent 
to controls or below (Tables 4.30 and 4.31). 
4.8.2.2. Hepatic ALA-synthetase 
The activity of hepatic ALA-synthetase was assayed in uninduced rats 
sacrificed 3 hours after the second and sixth injections of halothane. 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































administered (details are given in Table 4.32). The changes in the 
activity of hepatic ALA-synthetase corresponded to the changes observed 
in the levels of urinary haem precursors after chronic halothane treat-
ment (cf. Tables 4.28 - 4.31) in that ALA-synthetase activity was signi-
ficantly increased after the second injection of halothane but was 
decreased to control values following the sixth injection of halothane 
(Table 4.32). 
4.9. THE EFFECTS OF HALOTHANE IN VITRO 
4.9. 1. The effects of halothane on the levels of hepatic microsomal 
cytochrome P-450 and haem in microsomes from phenobarbital 
induced rats in vitro 
The levels of hepatic microsomal cytochrome P-450 and haem were decreased 
following the incubation of halothane with reaction mixtures containing 
hepatic microsomes, EDTA and NADPH-generating system (Table 4.33). The 
losses of hepatic microsomal haem were equivalent to the corresponding 
losses of microsomal cytochrome P-450 in reaction mixtures incubated 
with halothane for Oto 15 min. However, in reaction mixtures incubated 
with halothane for 25 and 30 min, the losses of hepatic microsomal haem 
appeared to be less than the corresponding losses of microsomal cytochrome 
P-450 (P < 0.05) (Table 4.33). Incubation of reaction mixtures for 
30 min from which either the halothane or the NADPH-generating system 
was omitted did not result in substantial losses of hepatic microsomal 
cytochrome P-450 or haem (Table 4.33). 
A significant increase in the production of cytochrome P-420 was observed 
following 30 min incubations of reaction mixtures containing hepatic 
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TABLE 4.32 
THE EFFECTS OF CHRONIC HALOTHANE TREATMENT ON THE ACTIVITY OF HEPATIC 
ALA-SYNTHETASE IN UNINDUCED RATS 
Uninduced rats were injected with halothane (1.0 ml/kg) every 48 hours. 
The rats were sacrificed 3 hours after the second and sixth injection 
of halothane. Day 1 - where no halothane had as yet been administered 
to the rats - was regarded as the control. Results are reported as 
means+ S.D. for determinations in triplicate on each of two or more 
groups of three rats. 
DAY NO. OF HALOTHANE ALA-SYNTHETASE 
INJECTIONS µg ALA formed/mg % Relative to 
protein/30 min controls 
0 0.003 + 0.001 100 
5 2 0.008 + 0.002* 267 
13 6 0.004 + 0.001 133 
Abbreviation: ALA, 6-aminolevulinic acid. 
* Differs significantly from control rats, P < 0.01. 
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TABLE 4.33 
THE EFFECTS OF HALOTHANE ON THE LEVELS OF HEPATIC MICROSOMAL CYTO-
CHROME P-450 AND HAEM IN VITRO 
Hepatic microsomes (2 mg protein/ml) from phenobarbital induced Wistar 
rats, NADPH-generating system and EDTA (0.2 mM) were incubated in the 
abse~ce or presence of halothane (18 mM) at 30°c with shaking at 60 cycles 
per min as described in Section 3.3. For the cytochrome P-450 assay, 
reference cuvettes contained 3 ml of hepatic microsomal suspension 
(2 mg protein/ml) incubated at 30°C with shaking. Each value corresponds 
to assays in triplicate or quadruplicate on each of three to four separate 
preparations of hepatic microsomes, which were prepared from groups of 
3 to 5 rats each unless otherwise indicated. Reported losses are rela-
tive to zero time samples of identical composition, assayed at 30°. 
Reported values are means~ S.D. Initial levels in nmoles/mg microsomal 
protein were:cytochrome P-450, 1.9; haem, 2.8. 
ADDITIONS INCUBATION TIME CYTOCHROME P-450 LOSS HAEM LOSS 
min nmoles/mg nmoles/mg 
mic. protein mic. protein 
Halothane* 3 0.26 + 0.08 0.27 + 0. 16 -
Halothane 5 0.22 + 0.03 0.24 + 0. 15 
Halothane 10 0.31 + 0.11 0. 30 + 0. 13 
Halothane 15 0.34 + 0. 10 0.30 + 0. 11 
Halothane* 25 0.91 + 0.09 0.64 + 0.06* 
Halo thane 30 0.81 + 0. 15 0.65 + 0.36 =!=§ 
None 30 0.19 + 0.09 0.26 + 0.12 
Halothane + 30 0.15 + 0.08 0.18+0.15 
Abbreviation: mic., microsomal. 
* Assay on one preparation of hepatic microsomes only. 
+ NADPH-generating system omitted from incubation mixtures. 
* Probably differs from corresponding loss of cytochrome P-450, P < 0.05. 
§ Statistical analysis was performed using Student's t-test for paired data. 
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microsomes, NADPH-generating system, EDTA and halothane relative to 
30 min incubations of reaction mixtures from which either the halo-
thane or the NADPH-generating system were omitted (Table 4.34). This 
is consistent with the difference between the losses of cytochrome 
P-450 and haem observed in reaction mixtures incubated with halothane 
for 30 min. However, it was not possible to assess the production 
of cytochrome P-420 as a function of time,since vortexing halothane 
into the reaction mixtures at time zero produced measurable levels of 
cytochrome P-420, and these levels decreased with time in incubation 
mixtures containing halothane and hepatic microsomes (data not shown). 
Theseresults differ quantitatively but not qualitatively from the reports 
that halothane in part converts cytochrome P-450 to cytochrome P-420 
and in part appears to modify the haem moiety of this enzyme in hepatic 
microsomes in vitro (16). 
4.10. THE EFFECTS OF HALOTHANE ON DIFFERENT FORMS OF HEPATIC MICROSOMAL 
CYTOCHROME P-450 
Since halothane causes the degradation of hepatic microsomal cytochrome 
P-450, attempts were made to ascertain which of the multiple forms of 
cytochrome P-450 were preferentially degraded by halothane ~ vitro and 
~ _vivo by the use of various enzyme assays. Determination of the 
rate of ethoxyresofurin deethylation was thought to be characteristic 
primarily of the major polycyclic hydrocarbon-inducible form of cyto-
chrome P-450 whereas determination of the metyrapone-ferrocytochrome 
P-450 complex was considered to be characteristic primarily of the 
major phenobarbital-inducible form of cytochrome P-450 under the 
conditions of our experiments (260, 265, 282). 
136 
TABLE 4.34 
THE EFFECT OF HALOTHANE ON THE PRODUCTION OF CYTOCHROME P-420 IN 
HEPATIC MICROSOMES FROM PHENOBARBITAL TREATED RATS IN VITRO 
Experimental details are as given in Table 4.33. Results for each 
experiment are means for determinations in triplicate on a single prepara-
tion of hepatic microsomes prepared from a group of 3 to 5 rats. Indi-






































* 6A = absorbance units, calculated as described in Fig. 4.4. 
+ NADPH-generating system was omitted from incubation mixtures. 
i Differs significantly from reaction mixtures from which either halothane 












THE EFFECT OF HALOTHANE ON THE PRODUCTION OF CYTOCHROME P-420 IN VITRO 
AND THE METHOD OF CALCULATION OF THE ABSORBANCE DUE TO CYTOCHROME P-420 
Method of calculation of cytochrome P-420: 




































450 Wavelength (nm) 490 
Absorbance spectrum of hepatic microsomes from phenobarbital induced rats. 
(-) incubated with halothane, NADPH-generating system and EDTA for 30 min, 
(·-1 incubated with NADPH-generating system and EDTA for 30 min. 
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4.10.1. The effects of halothane on the levels and activities of 
different forms of cytochrome P-450 in microsomes from 
phenobarbital induced rats in vitro 
Following incubation of halothane with hepatic microsomes from pheno-
barbital induced rats, EDTA and NADPH-generating system, the levels 
of hepatic microsomal cytochrome P-450 were decreased relative to 
zero time samples (Table 4.35). At both 15 min and 30 min after 
halothane treatment in vitro the levels of the major phenobarbital-
inducible form of cytochrome P-450 were significantly decreased rela-
tive to zero time samples. The losses of the major phenobarbital-
inducible form of cytochrome P-450 were equivalent to the losses of 
cytochrome P-450 (in nmoles per mg of microsomal protein) (Table 4.35). 
In contrast, halothane caused no significant change in the activity 
of ethoxyresofurin deethylase j__!! vitro (Table 4.35). 
4. 10.2. The effects of halothane on the levels and activities of 
different forms of cytochrome P-450 in phenobarbital 
induced rats in vivo 
Fol:ov1ing halothane treatment j__!! vivo, the levels of hepatic 
microsomal cytochrome P-450 were significantly decreased relative to 
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A significant decrease in the levels of the major phenobarbital-inducible 
form of cytochrome P-450 was observed 30 and 60 min after halothane 
treatment~ vivo (Table 4.36). At the latter time point, viz. 60 min 
after halothane treatment, the loss of the major phenobarbital-inducible 
form of cytochrome P-450 was equivalent to the loss of cytochrome P-450 
in nmoles per mg of microsomal protein. A small decrease in the 
activity of ethoxyresofurin deethylase was observed 30 and 60 min after 
halothane treatment in vivo (Table 4.36). 
4. 11. ACUTE TRICHLOROETHYLENE TREATMENT 
4.11. 1. The effects of trichloroethylene on hepatic microsomal enzymes 
and haem in induced and uninduced rats 
4.11.1. 1. Cytochrome P-450 and haem. 
The effects of acute trichloroethylene treatment on the levels of 
hepatic microsomal cytochrome P-450 and haem were determined in pheno-
barbital induced and uninduced Wistar rats (Table 4.37). Significant 
decreases in the levels of cytochrome P-450 and haem were observed in 
both phenobarbital induced and uninduced rats 24 hours after trichloro-
ethylene treatment. The losses of cytochrome P-450 and haem in nmoles/ 
mg of microsomal protein were greater in phenobarbital induced than in 
uninduced rats, although the percentage loss of cytochrome P-450 was 
greater in uninduced than in phenobarbital induced rats. The losses 
of haem were similar to the losses of cytochrome P-450 in all experi-

































































































































































































































































































































































































































































































































































































































































4.11. 1.2. Haem oxygenase. 
Twenty-four hours after acute trichloroethylene treatment, significant 
increases in the activity of hepatic haem oxygenase were observed in 
both phenobarbital induced and uninduced rats. However, a greater in-
crease in haem oxygenase activity was observed in uninduced rats than 
in phenobarbital induced rats (Table 4.37). 
4.11.2. The effects of trichloroethylene on the hepatic haem biosynthetic 
pathway in induced and uninduced rats 
The effects of acute trichloroethylene treatment on the levels of urinary 
precursors in induced and uninduced rats are shown in Table 4.38. No 
significant changes in the levels of urinary haem precursors were observed 
in uninduced rats after acute trichloroethylene treatment. A signi-
ficant increase in the levels of porphobilinogen was observed in the 
urine of phenobarbital induced rats after acute trichloroethylene 
treatment, but the levels of the other urinary haem precursors measured, 
viz. ALA, uroporphyrin and coproporphyrin were unchanged relative to 
control animals (Table 4.38). 
No significant changes in the activity of ALA-synthetase were observed 
in either phenobarbital induced or uninduced rats, 24 hours after acute 
trichloroethylene treatment. The percentages of the enzyme activity 
after trichloroethylene treatment relative to its activity in identically 
induced rats not receiving trichloroethylene were as follows:-



































































































































































































































































































































































































































































































































































































































































4. 12. CHRONIC TRICHLOROETHYLENE TREATMENT 
4.12.1. The effects of chronic trichloroethylene treatment on the levels 
of haem precursors in uninduced rats 
Uninduced rats were injected with trichloroethylene (1.0 ml/kg) every 
48 hours. Urine and faeces were collected from two groups of three 
identic~lly treated rats over a period of 48 hours, commencing immedi-
ately after each trichloroethylene injection. Day l - where no tri-
chloroethylene had as yet been administered to the rats - was regarded 
as the control for each experiment. 
The results of two experiments showing the effects of chronic trichloro-
ethylene treatment on the levels of urinary and faecal haem precursors 
over a period of 19 days (or 8 injections of trichloroethylene) are 
reported in Tables 4.39 - 4.44. The levels of urinary ALA were probably 
significantly increased relative to control values after the first and 
second injections of trichloroethylene but subsequently decreased until 
the levels were unchanged relative to control levels or below (Table 
4.39). Urinary porphobilinogen levels were increased relative to control 
values (P < 0.05) after the first injection of trichloroethylene but in 
general porphobilinogen levels remained unchanged relative to control 
levels for the remainder of the experiments (P > 0.1) (Table 4.40). 
However, uroporphyrin levels were strikingly elevated after the first 
injection of trichloroethylene in both experiments and remained elevated 
until the sixth injection of trichloroethylene, after which the levels 
of uroporphyrin decreased to control levels (Table 4.41). Urinary 
coporporphyrin levels were also strikingly elevated after the first and 
second injections of trichloroethylene but the levels gradually decreased 
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Faecal coporporphyrin and protoporphyrin levels were elevated after the 
second injection of trichloroethylene relative to control values but 
the levels remained unchanged throughout the rest of the experiments 
(Tables 4.43, 4.44). 
4.13. ACUTE TETRACHLOROETHYLENE TREATMENT 
4. 13.l. The effects of tetrachloroethylene on hepatic microsomal 
enzymes and haem in phenobarbital induced rats 
4. 13.1. 1. Cytochrome P-450 and haem. 
The effects of acute tetrachloroethylene on the levels of hepatic micro-
somal cytochrome P-450 and haem were assessed in phenobarbital induced 
Wistar rats (Table 4.45). A single injection of tetrachloroethylene 
into phenobarbital induced rats resulted in a significant decrease in 
the levels of hepatic microsomal cytochrome P-450, but not of microsomal 
haem (Table 4.45). 
4. 13. 1.2. Haem oxygenase. 
A slight increase in the activity of hepatic haem oxy9enase was 
observed after acute tetrachloroethylene treatment of phenobarbital 
induced rats (Table 4.46). 
4. 13.2. The effects of tetrachloroethylene on hepatic haem biosynthesis 
in phenobarbital induced rats 
Acute tetrachloroethylene treatment of phenobarbital induced rats caused 
no significant alteration in the levels of the urinary haem precursors 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results presented in this thesis demonstrate that intraperitoneal 
administration of the anaesthetic agents, fluroxene, halothane and 
trichloroethylene, caus~a decrease in the levels of hepatic microsomal 
cytcchrome P-450 _j_.!]_ vivo and also affectsthe rates of hepatic haem bio-
synthesis and biodegradation (Sections 4.1 - 4.13). Several aspects 
of these findings will be discussed in detail, namely: 
(1) The diverse ways in which these compounds decrease the levels of 
cytochrome P-450; 
(2) The role of the extent and the type of destruction of cytochrome 
P-450 in causing alterations in the rates of hepatic haem biosyn-
thesis and biodegradation; and 
(3) Other mechanisms whereby these and other chemicals might affect 
the rates of haem metabolism in the liver. 
In view of their effects on haem biosynthesis in the rat, the three 
anaesthetic agents will be assessed as providing possible experimental 
models for human genetic porphyria. 
As n~ntioned in the Introduction (Section 1.6), the levels of hepatic 
microsomal cytochrome P-450 have been postulated by several workers to 
be an important factor in determining the rates of hepatic haem biosyn-
thesis and biodegradation (133, 215, 283, 284). The effects of cyto-
chrome P-450 on hepatic haem metabolism are thought to arise from 
(a) the ability of the apoprotein of cytochrome P-450 to draw haem from 
a central hepatic pool of haem which regulates the rates of hepatic haem 
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biosynthesis and biodegradation (Section 1.6) and (b) the ability of 
cytochrome P-450 to dissociate into haem and apoprotein, with the 
haem entering the central haem pool (Section 1.6). 
It has been found that several xenobiotics which alter the levels of 
hepatic cytochrome P-450, perturb haem biosynthesis (215, 285) and/or 
haem biodegradation (133, 284) (cf. Sections 1.8.1.3 and 1.9). For 
example, the chemical AIA, which degrades the haem moiety of hepatic 
microsomal cytochrome P-450 (Section 1.8. 1.3) (121, 245, 246) is 
commonly used to induce a state of experimental porphyria in labora-
tory animals. 
5. 1. FLUROXENE 
At the onset of this project, the degradation of hepatic microsomal 
cytochrome P-450 by the anaesthetic agent fluroxene (Section 1.3.1) 
appeared to be similar to that mediated by AIA (Section 1.8.1.3) in 
that both chemicals specifically degraded the haem moiety of the 
enzyme and the reaction kinetics of the degradation reaction were, 
in both cases, pseudo first order (136). Thus it was decided to 
determine the effects of fluroxene on hepatic haem metabolism~ vivo 
in order to test the proposal that an alteration in the levels of cyto-
chrome P-450 can affect haem metabolism (Section 1 .6) (133, 215, 283, 284). 
In our initial experiments, it was confirmed that intraperitoneal 
administration of fluroxene to Wistar rats resulted in the degradation 
of the haem moiety of hepatic microsomal cytochrome P-450, i.e. the 
loss of microsomal haem was equivalent to the loss of cytochrome P-450 
(in nmoles per mg of microsomal protein) after acute fluroxenetreatment 
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+ (Table 4.1) . 
Acute fluroxene treatment also resulted in increases in the rates of 
both hepatic haem biosynthesis and biodegradation (Tables 4.2 - 4.7). 
The effects of fluroxene on hepatic haem metabolism appeared to be 
related to the fluroxene mediated degradation of cytochrome P-450, 
since TFEE (Fig. 1.5), the saturated analogue of fluroxene, which does 
not cause degradation of hepatic cytochrome P-450 (Table 4.8) (65, 72, 
135) did not affect hepatic haem biosynthesis or biodegradation 
(Tables 4.8, 4.9). Furthermore, in general, pretreatment of the 
experimental animals with phenobarbital or 3-methylcholanthrene en-
hanced both the fluroxene mediated degradation of cytochrome P-450 and 
the effects of fluroxene on the pathways of hae~ biosynthesis and bio-
degradation (Tables 4. 1 - 4.7). 
Tl'ie specifics of the effects of fluroxene on hepatic haem metabolism 
are discussed below: 
Firstly, acute fluroxene treatment resulted in an increase in the 
activity of the rate-limiting enzyme of haem biosynthesis, ALA-
synthetase (Fig. 1.11) (Table 4.7). Hepatic ALA-synthetase has been 
+ Although fluroxene contains 0.01% N-phenyl-l-naphthylamine 7 an anti-
oxidant which may be capable of stimulating lipid peroxidation, the 
effects of fluroxene on hepatic microsomal cytochrome P-450 do not 
appear to arise from lipid peroxidation since experiments with 
fluroxene in vitro were conducted in the presence of EDTA, which is 
an inhibitor of lipid peroxidation. In addition, pronounced degrada-
tion of cytochrome P-450 by fluroxene occurred under conditions where 
lipid peroxidation was negligible (as assessed by malonaldehyde 
production) (65). 
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found to be induced by a variety of hydrophobic compounds (286,287). 
Induction of hepatic ALA-synthetase has been attributed to a derepres-
sion of the synthesis of the enzyme, caused by a loss of haem from the 
regulatory haem pool which decreases the feedback inhibition of haem 
on ALA-synthetase (215, 220, 286). Therefore, the induction of ALA-
synthetase observed in fluroxene treated rats (Table 4.7) is presumably 
due to a loss of haem from the hepatic haem pool which regulates the 
activity of ALA-synthetase). 
There appear to be two possible mechanisms by which fluroxene could 
deplete the hepatic haem pool. Firstly, large amounts of hepatic haem 
are presumably required to replace the haem of hepatic cytochrome P-450 
degraded by fluroxene (Table 4.1). Secondly, acute fluroxene treatment 
resulted in an increase in the rate of hepatic haem biodegradation 
(Tables. 4.2, 4.3} which could further deplete hepatic haem levels in 
the regulatory haem pool and lead to the induction of ALA-synthetase 
(Table 4. 7). 
The fluroxene mediated induction of hepatic ALA-synthetase (Table 4.7) 
resul.ted in an increase in the rate of hepatic haem biosynthesis in 
fluroxene treated animals, i.e. increases in the levels of the urinary 
haem precursors ALA and porphobilinogen were observed after acute 
fluroxene treatment (Table 4.4). However, in general, no significant 
increases in the levels of the urinary and faecal porphyrins were 
observed after fluroxene treatment (Tables 4.5, 4.6). This would 
appear to arise from a situation where uroporphyrinogen synthetase 
(Fig. 1.11) is the rate-limiting enzyme of the haem biosynthetic pathway. 
This enzyme normally functions at a marginally greater rate than ALA-
synthetase, which is, under normal circumstances, the rate-determining 
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enzyme of haem biosynthesis (153, 154). Uroporphyrinogen synthetase 
may therefore simply become the rate-limiting step in haem biosynthesis 
because the activity of ALA-synthetase is elevated (288). Alternatively, 
it is possible that acute fluroxene treatment may have decreased the 
activity of this enzyme, as was found after the chronic exposure of 
animals to fluroxene (Section 4.3). 
As mentioned earlier, acute fluroxene treatment was also found to cause 
a pronounced elevation in the rate of hepatic haem biodegradation, i.e. 
an increase in the activity of hepatic haem oxygenase was observed 
after treatment with fluroxene (Table 4.2). The elevation of this 
enzyme in fluroxene treated rats appeared to be linked to the fluroxene 
mediated degradation of cytochrome P-450 since, following fluroxene 
treatment of differently induced animals, there was a direct relation-
ship between the loss of the haem of hepatic microsomal cytochrome P-450 
and the increase in hepatic haem oxygenase activity (Table 4.2). 
Furth~rmore, the degradation of cytochrome P-450 occurred prior to 
the elevation of hepatic haem oxygenase in fluroxene treated rats 
(Table 4.3), which is consistent with the suggestion that the induction 
of hepatic haem oxygenase may be a consequence of the fluroxene 
mediated degradation of cytochrome P-450. 
In contrast to the effects of fluroxene on hepatic haem oxygenase 
activity, AIA, which also degrades the haem moiety of hepatic micro-
somal cytochrome P-450 (Section 1.8.l.3) does not affect the activity 
of hepatic haem oxygenase _j_~ vivo (248). Thus the degradation of the 
haem moiety of hep.atic cytochrome P-450 does not in itself appear to 
be the only prerequisite for the induction of hepatic haem oxygenase 
in fluroxene treated animals. It is possible that the adduct of 
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fluroxene with the haem of cytochrome P-450 (which differs in structure 
from the AIA-haem adduct (Sections 1.3.1, 1.8.1.3)) induces the activity 
of hepatic haem oxygenase. Alternatively, it is possible that the 
fluroxene mediated increase in hepatic haem oxygenase activity arises 
from elevated levels of ferric ions, which were perhaps released from 
the fluroxene-haem adduct. The de novo induction of hepatic haem 
oxygenase by haem as well as by certain heavy metals, including iron, 
has been well documented (289-294). 
The concurrent increases in the activities of hepatic ALA-synthetase 
and hepatic haem oxygenase which were observed after acute fluroxene 
treatment (Tables 4.2, 4.7) were unexpected, since an increase in 
hepatic ALA-synthetase activity is associated with a loss of haem from 
the regulatory haem pool (215, 220), whereas an increase in haem oxygen-
ase activity is generally thought to be a consequence of an increase in 
the level of haem in the regulatory pool (295) (Section 1.6). In order 
to determine more precisely the mechanisms by which acute fluroxene 
treatment affects hepatic haem metabolism, experiments should be per-
formed in which the levels of ALA-synthetase, haem oxygenase and cyto-
chrome P-450 are determined as a function of time after fluroxene admin-
istration (similar to the experiment described in Tdble 4.3). Changes 
in the levels of haem in the regulatory haem pool should also be 
monitored at various time intervals after fluroxene treatment - an 
experiment which is just becoming feasible via sensitive techniques 
such as chemiluminescence (296). Furthermore, the effects of the 
adduct of fluroxene with the haem of cytochrome P-450 on hepatic haem 
oxygenase should be assessed. 
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With a view to determining the effects of the fluroxene-haem adduct 
on hepatic haem oxygenase activity, we attempted to isolate and charac-
terize this adduct in our laboratory (Sections 3.8, 4.5). The results 
of our experiments indicated that the haem adduct was an N-substituted 
porphyrin (Section 4.5) (Fig. 4.1). This was later confirmed by 
Kunze et~ (138) who identified the haem adduct as N-(2-oxo-ethyl)-
protoporphyrin IX. The identical N-substituted porphyrin has also 
been identified in the liversof rats treated with vinyl fluoride, vinyl 
bromide and acetylene (297). The formation of the same haem adduct 
by a11 four substrates indicates that an oxygen is introduced at the 
trifluoroethoxy or halide substituted terminus of the rr bond, followed 
by reaction of the unsubstituted terminus with the nitrogen atom of the 
haem of cytochrome P-450 (297). The most recent investigations into 
the formation of N-(2-oxo-ethyl)-protoporphyrin IX suggest that the 
fluroxene mediated alkylation of cytochrome P-450 prosthetic haem 
occurs via a radical intermediate (297) and not via a cationic inter-
mediate as previously suggested (69). However, the precise mechanism 
of formation of the haem adduct remains to be elucidated. 
Once the fluroxene-haem adduct had been isolated and characterized in 
our laboratory, it v1as attempted to assess the effects of this compound 
on hepatic haem oxygenase activity~ vitro. Under the conditions of 
our experiments, the isolated adduct did not affect hepatic haem 
oxygenase activity (results not shown). However, these results should 
be viewed with circumspection due to the instability of the isolated 
adduct+ and the.observation that the isolation procedure used resulted 
+ The isolated adduct, N-(2-oxo-ethyl)-protoporphyrin IX, is highly 
unstable and decomposes overnight in liquid nitrogen {-195°C) 
(results not shown) (281, 297). 
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in the loss of the iron ion, which is thought to be an integral part 
of the haem adduct l.!! vivo (130, 297). Consequently, the effects of 
the isolated adduct on hepatic haem oxygenase activity_:!_!!_ vitro might 
differ from the effects of the adduct on this enzyme_:!_!!_ vivo. 
In contrast to acute fluroxene treatment, chronic fluroxene treatment 
of laboratory animals did not appear to affect the levels of hepatic 
microsomal cytochrome P-450 and the activity of hepatic haem oxygenase 
(Table 4. 10). Some effect of chronic fluroxene administration on these 
enzymes might have been evident if their activities had been assessed 
as a function of time. However, it is not unusual to observe different 
consequences of chronic versus acute administration of a drug (298). 
Chronic fluroxene treatment resulted in an increased rate of hepatic 
haem biosynthesis (Tables 4.11 - 4.17) which was far more striking 
than that observed after acute fluroxene administration (Tables 4.4 -
4.7). The induction of hepatic haem biosynthesis after chronic 
fluroxene treatment appears to arise from a different mechanism than 
that proposed for acute fluroxene administration. While the ability 
of acute fluroxene treatment to induce hepatic haem biosynthesis appears 
to be a consequence of the fluroxene mediated degradation of hepatic 
microsrnn~l cytochrome P-450 (Table 4.1), it is proposed that the ability 
of chronic fluroxene treatment to stimulate hepatic haem biosynthesis 
is a result of the inhibition of hepatic uroporphyrinogen synthetase 
in these animals (Table 4.17). 
Prolonged administration of fluroxene to uninduced animals produced 
a pronounced decrease (approximately 50%) in the activity of hepatic 
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uroporphyrinogen synthetase (Table 4.17). The decreased activity of 
hepatic uroporphyrinogen synthetase after chronic fluroxene treatment 
would cause a partial block in hepatic haem biosynthesis and would 
thereby decrease the repression of ALA-synthetase by haem,thus explaining 
the observed elevation in the activity of the latter enzyme (Table 4.17) 
(299, 300), Consistent with the above effects, increased levels of 
porphobilinogen and to a lesser extent, ALA, were observed in the urine 
of animals after chronic fluroxene treatment (Tables 4.11, 4.12) (266). 
The mechanism responsible for the decrease in hepatic uroporphyrinogen 
synthetase activity observed after chronic fluroxene treatment of 
animals, is not known. It does not appear to be related to excessive 
ALA-synthetase activity~ since the activity of uroporphyrinogen synthetase 
is not diminished by induction of ALA-synthetase in rats treated with AIA 
(301). In addition, high concentrations of porphobilinogen do not appear 
to inhibit uroporp.hyrinogen synthetase activity (299), 
A possible explanation for the observed decrease in the activity of uro-
porphyrinogen synthetase after chronic fluroxene treatment is that 
fluroxene, or a metabolite thereof, is directly affecting the activity 
or levels of this enzyme. However, neither fluroxene nor its metabolites 
2,2,2-trifluoroethanol (TFE), trifluoroacetic acid and trifluoroacetalde-
hyde had any effect on the activity of hepatic uroporphyrinogen synthe-
tase in vitro (Table 4.19), --~ It appeared possible therefore, that the 
haem adduct produced by fluroxene treatment could inhibit hepatic uro-
. porphyri nogen synthetase. The ability of the haem adduct produced by 
DOC tre~tment of animals, namely N-methylprotoporphyrin IX, to inhibit 
the- enzyme. of the haem biosynthetic pathway, ferrochelatase, is well 
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documented (237-239). Thus attempts were made to assess the effects 
ofthe isolated fluroxene-haem adduct on hepatic uroporphyrinogen syn-
thetase in vitro (Table 4.20). Although, under the conditions of our 
experiments, the fluroxene-haem adduct caused no change in the activity 
of hepatic uroporphyrinogen synthetase (Table 4.20), these results are 
not conclusive in view of [l] the instability of the isolated adduct 
(281, 297), [2] the presence of high concentrations of acid in the 
isolated product which required neutralization, a process which resulted 
in the partial destruction of the adduct (results not shown), and [3] 
the probable loss of the iron ion of the adduct due to the isolation 
procedures used (see above) (297). Thus further experimentation is 
required in order to assess the proposal that the haem adduct is associa-
ted with the inhibition of hepatic uroporphyrinogen synthetase following 
chronic fluroxene treatment. Furthermores since the same haem adduct 
is produced by not only fluroxene, but also vinyl fluoride, vinyl bromide 
and acetylene, the effects of these compounds on hepatic haem biosynthesis 
and in particular, hepatic uroporphyrinogen synthetase could be determined 
in vivo. If the haem adduct is indeed responsible for the inhibition 
of hepatic uroporphyrinogen synthetase after chronic fluroxene treatment, 
chronic administration of vinyl fluoride, vinyl bromide and acetylene to 
experimental animals would be expected to produce similar results to 
those observed after chronic fluroxene treatment, viz. inhibition of 
hepatic uroporphyrinogen synthetase~ induction of hepatic ALA-synthetase 
and increased levels of porphobilinogen and to a lesser extent, ALA. 
The effects of chronic fluroxene administration on the hepatic haem bio-
synthetic pathway, in particular the inhibition of uroporphyrinogen syn-
thetase, are extremely relevant to the study of the human genetic diseases 
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known as the porphyrias (Section 1.7). One of the several types of 
acute porphyrias, namely Acute Intermittent Porphyria (AIP) is charac-
terized biochemically by a defect in the activity of hepatic uroporphyrin-
ogen synthetase. In AIP the activity of this enzyme is reduced to 
approximately 50% of normal levels (302-304). This enzyme defect is 
transmitted as an autosomal dominant and manifests itself in all tissues, 
including the liver (302). 
The precise nature of the inherited defect in uroporphyrinogen 
synthetase is now known. Anderson and Desnick (J. Clin. Invest. 68, 
1 (1981~have purified the enzyme and provided a detailed scheme for 
its mechanism and alteration in porphyric individuals. 
The decreased activity of uroporphyrinogen synthetase results in second-
ary derepression of hepatic ALA-synthetase and over-production of the 
p-0rphyrin precursors, ALA and porphobilinogen (Table 1.5, Fig. 1.16)(305). 
The increased urinary excretion of these substances is the main biochem-
ical feature of AIP (305). 
Thus it can be seen that prolonged administration of fluroxene produces 
a biochemical picture which closely resembles AIP, and therefore chronic 
fluroxene treatment of animals could possibly be used as a model system 
for studying AIP. This would be an extremely useful model system, 
since it provides a mammalian system for study~ vivo, rather than in 
an in vitro system, such as chick embryo, which may be of dubious 
relevance to mammals. Furthermore, at present, no good experimental 
mode1 exists for the study of AIP (cf, Table 1.6), and therefore chronic 
fluroxene treatment of animals could prove to be a new and valuable model 
system for the study of AIP. Experiments are currently being performed 
overseas with a view to establishing chronic fluroxene treatment as a 
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model system for human AIP. 
Recently, a model system has been established in experimental animals 
whereby it is possible to reproduce experimentally the sensitivity of 
the human acute porphyric patient to lipid-soluble drugs (Section 1.8.2.) 
(228). Animals given a relatively small dose of DOC exhibit an experi-
mental porphyria which closely resembles an acute hepatic porphyria 
(Variegate Porphyria (Section 1.7 )) in its latent state, since these rats 
become very sensitive to drugs that can exacerbate the metabolic disorder, 
changing the biochemical picture to that typical of the human acute attack 
of porphyria (228, 306). Thus DOC treated rats have proved useful in 
assessing the porphyrogenicity of drugs and whether they might be poten-
tially hazardous to the human who carries acute porphyria in the latent 
state (306, 307). Anderson (307) has stated that all chemicals and 
drugs which have been demonstrated to induce ALA-synthetase in these 
rats 1 should be avoided in patients with acute porphyria. 
Since fluroxene was found to stimulate ALA-synthetase in DOC treated rats 
(Table 4.18 ), it could be regarded as being potentially hazardous for 
use in porphyric patients. Furthermore, in agreement with these results, 
Moore (309) has listed fluroxene as a drug to be avoided by patients with 
acute hepatic porphyria. 
5.2. TRICHLOROETHYLENE 
The results of previous experiments have shown that the anaesthetic 
agent, trichloroethylene, degrades the haem moiety of hepatic microsomal 
cytochrome P-.450 ~~~and in vitro+ (Section 1.3.3 ) (99, 100, 107). 
+ Since trichloroethylene does not contain any antioxidant, and EDTA (an 
inhibitor of lipid peroxidation) is present in all experiments performed 
in vitro, the observed trichloroethylene mediated degradation of cyto-
chrome P-450 does not appear to arise from lipid peroxidation. 
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In agreement with the above results, intraperitoneal administration of 
trichloroethylene to Wistar rats was found to decrease the levels of 
hepatic microsomal cytochrome P-450 ~ vivo (Table 4.37 ). Further-
more, this degradation reaction appeared to affect the haem moiety of 
cytochrome P-450 since the losses of microsomal haem were equivalent 
to the losses of cytochrome P-450 (in nmoles per mg of microsomal 
protein) after trichloroethylene treatment of uninduced and phenobarbital 
induced Wistar rats (Table 4.37 ). Thus the trichloroethylene mediated 
degradation of cytochrome P-450 appeared to be similar to the fluroxene 
(and AIA) mediated degradation of cytochrome P-450 ..:!..!!. vivo (cf. Sections 
1.3. l , 1.8.1.3 , 4.1.1 ) . However, unlike fluroxene and AIA, it is 
not known whether trichloroethylene forms an adduct with the haem moiety 
of cytochrome P-450. 
Since the fluroxene and AIA mediated degradations of cytochrome P-450 
were thought to be associated with the pronounced effects of these chemi-
cals on hepatic haem metabolism (Sections 1.8.l.3 , 4.1 , 5.1 ) it was 
anticipated that trichloroethylene treatment would also affect these 
pro:esses ~ vivo. However, no change in ALA-synthetase activity and 
little or no change in urinary haem precursor levels \'Jere observed after 
acute trichloroethylene treatment~ vivo (Sections 4.11.2 ) (Table 4.38 ). 
Acute trichloroethylene treatment did cause a significant increase in 
hepatic.: haem oxygenase activity..:!..!!_ vivo (Table 4.37 ). These results 
are surprising ~ince the degradation of the haem of hepatic microsomal 
cytochrome P-450 would be expected to cause a decrease in haem levels 
in the regulatory haem pool (Section 1.6.) which would in turn result 
in an increase in the activity of ALA-synthetase and an increase in 
haem biosynthesis with little or no change in the activity of hepatic 
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haem oxygenase (cf. AIA: Section 1.8.1.3 ). The lack of effect of 
trichloroethylene on hepatic ALA-synthetase activity (Section 4. 11.2 ) 
may reflect the time at which this enzyme was assayed, viz. 24 hours 
after acute trichloroethylene treatment: The increase in urinary 
porphobilinogen levels after trichloroethylene treatment of pheno-
barbital induced rats (Table 4.38) suggests that a slight increase in 
the rate of haem biosynthesis did occur over the 24 hour collection 
period, but the increase was perhaps too small and/or too transient to 
cause any striking changes in haem precursor levels. 
The increase in hepatic haem oxygenase activity observed after acute 
trichloroethylene treatment appeared to be related to the trichloro-
ethylene mediated degradation of the haem moiety of hepatic microsomal 
cytochrome P-450 since tetrachloroethylene (the symmetrically substi-
tuted analogue of trichloroethylene (Section 1.2.4 )) which caused only 
a slight decrease in hepatic cytochrome P-450 levels and no change in 
microsomal haem levels (Table 4,45 ), only slightly increased the 
activity of hepatic haem oxygenase (Table 4.46 ) and caused no change 
in hepatic haem biosynthesis (Tables 4.46 , 4.47 ). 
The mechanism by which trichloroethylene mediates the increase in hepatic 
haem oxygenase activity is unknown. It does not appear to be associated 
with an increase in the levels of haem in the regulatory pool since tri-
chloroethylene does not appear to cause the dissociation of intact haem 
from hepatic cytochrome P-450. On the other hand, the increase in 
haem oxygenase activity observed after acute trichloroethylene treat-
ment (Table 4.37 ) may be due to induction of this enzyme; perhaps by 
a trichloroethylene haem adduct or a breakdown product of cytochrome 
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P-450 haem, as was suggested for the fluroxene mediated induction of 
hepatic haem oxygenase (Section 5.1 ). 
In general, the effects of trichloroethylene on hepatic haem metabolism 
appeared to differ from the effects of fluroxene on these processes~ 
Whereas acute fluroxene treatment caused pronounced increases in the 
rates of hepatic haem biosynthesis and biodegradation (Sections 4.1,5.1), 
acute trichloroethylene treatment appeared to only significantly affect 
hepatic haem biodegradation (Tables 4.37 , 4.38 ). The differences in 
the effects of these two compounds on hepatic haem metabolism may 
reflect different mechanisms of degradation of hepatic microsomal cyto-
chrome P-450 by these two compounds, or the preferential degradation 
of different forms of cytochrome P-450 i!!_ vivo (cf. fluroxene, Section 
1.3.1). Fluroxene is known to degrade the haem moiety of cyto-
chrome P-450 to an N-modified porphyrin, formed by alkylation of the 
haem prosthetic group of cytochrome P-450 by an oxygen activated form 
of fluroxene (Section 1.3.1 ). On the other hand, although a similar 
product has been postulated to be formed during the cytochrome P-450 
~diated oxidative metabolism of trichloroethylene (100), no green 
discolouration of the liver was observed after trichloroethylene treat-
ment.:!!: vivo or of hepatic microsomes following incubation in the 
presence of trichloroethylene and generating system i!!_ vitro (personal 
observation). However, these observations do not exclude the possibi-
lity that a haem adduct (or green pigment) was formed as a result of 
the trichloroethylene mediated degradation of cytochrome P-450, but in 
amounts which were too small to be observed or alternatively, the life-
time of which was extremely short. 
171 
In order to clarify whether different forms of cytochrome P-450 are 
preferentially degraded by trichloroethylene and fluroxene _j.!!_ vivo, 
the effects of these compounds on activities which are relatively 
specific for different forms of cytochrome P-450 were assessed (Table 
5. 1 ) ( 132) . Striking differences in the effects of the two anaes-
thetic agents on the different forms of cytochrome P-450 were observed 
(Table 5.1). Whereas fluroxene appears to preferentially degrade the 
major 3-methylcholanthrene-inducible form of cytochrome P-450 (as 
assessed by the activity of ethoxyresofurin deethylase) in phenobarbital 
induced rats, trichloroethylene did not appear to affect this form of 
cytochrome P-450 in phenobarbital induced rats _j.!!_ vivo (Table 5.1). 
In contrast, the activity of benzpyrene-3-hydroxylase, which is associa-
ted with multiple forms of polycyclic hydrocarbon-inducible cytochrome 
P-450, was decreased by trichloroethylene and not by fluroxene in pheno-
barbital induced rats (Table 5.1). The effects of fluroxene and tri-
chloroethylene on the phenobarbital-inducible forms of cytochrome P-450 
(as assessed by ethylmorphine demethylase and aminopyrine demethylase) 
were similar (Table 5.1). These results indicated that different 
forms of cytochrome P-450 were degraded by trichloroethylene and 
fluroxene _j.!!_ yivo and may account, in part, for the different effects 
. of these two compounds on hepatic haem metabolism in experimental 
animals. 
In contrast to the very slight effects of acute trichloroethylene treat-
ment on hepatic haem biosynthesis, chronic trichloroethylene treatment 






















































































































































































































































































































































































































































































































































































































































































































(Tables 4.39-4.44 ); in particular, the levels of urinary uroporphyrin 
and coproporphyrin were elevated 2 to 8 fold after the second through 
to the sixth injection of trichloroethylene (Tables 4.41 , 4.42 ), 
whereas the levels of ALA and porphobilinogen were only slightly elevated 
after the second trichloroethylene injection (Tables 4.39 , 4.40 ). 
These results indicate that the enzyme uroporphyrinogen decarboxylase may 
be inhibited by chronic trichloroethylene treatment, but that the activity 
of this enzyme should be determined after chronic trichloroethylene treat-
ment in order to clarify this suggestion. The observation that the 
levels of the haem precursors returned to control values after the sixth 
injection of trichloroethylene (Tables 4.39 - 4.44 ) implies that any 
enzyme defect (if present) was either temporary, or was overcome by the 
large increase in haem biosynthesis precipitated by chronic trichloro-
ethylene treatment. 
The above results are in striking contrast to the effects of chronic 
fluroxene treatment on hepatic haem biosynthesis. Whereas chronic 
treatment of trichloroethylene resulted in the temporary elevation of 
urinary uroporphyrin and coproporphyrin, chronic fluroxene treatment 
caused a prolonged and striking increase in the levels of porpho-
bilir.ogen and to a lesser extent ALA as a result of the fluroxene 
mediated inhibition of the enzyme uroporphyrinogen synthetase (Sections 
4.3 , 5~ 1 ). Thus the different patterns of precursors excreted after 
chronic trichloroethylene and fluroxene treatments may be explained by 
the observation that fluroxene inhibited uroporphyrinogen synthetase, 
whereas trichloroethylene may inhibit, to so~e extent, uropor-
phyrinogen decarboxylase. The explanation for the differ~nt effects 
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of the two compounds on hepatic haem biosynthesis, viz. decreased 
uroporphyrinogen synthetase as opposed to an apparent decrease in uro-
porphyrinogen decarboxylase is at present unknown. 
5.3. HALOTHANE 
Previous experiments have shown that halothane causes a decrease in 
the levels of hepatic microsomal cytochrome P-450 in vivo and l1!_ vitro 
(16, 78, 139). Results presented in this thesis confirm that [1] 
intraperitoneal administration of halothane to Wistar rats in vivo 
and [2] incubation of halothane with hepatic microsornes from Wistar 
rats l1!_ vitro, resulted in the loss of hepatic microsomal cytochrome 
P-450 (Tables 4.21 , 4.24 , 4.33 , 4.35 , 4.36 ). Prior metabolic 
activation of halothane by hepatic cytochrome P-450 appeared to be 
required for halothane to elicit its effects on cytochrome P-450 since 
the incubation of hepatic microsomes and halothane in vitro in the 
absence of an NADPH-generating system did not affect the levels of 
cytochrome P-450 (Table 4.33 ) (16). It appears that the halothane 
mediated loss of cytochrome P-450 primarily reflects the degradation of 
the phenobarbital-inducible form of the enzyme since the losses of the 
phenoJarbital-inducible form of cytochrome P-450 - as assessed by the 
metyrapone-ferrocytochrome P-450 complex - were identical (P > 0.1) to 
the losses of hepatic microsomal cytochrome P-450 (in nmoles per mg of 
microsomal protein) l1!_ vitro and~ vivo (Tables 4.35 , 4.36 ). This 
was recently confirmed by de Groot et~ (313) using halothane plus 
hepatic microsomes in vitro. 
The halothane mediated decrease of cytochrome P-450 appears to arise 
as a consequence of the presence of one or more reactive species produced 
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during the metabolism of halothane by cytochrome P-450 (cf. fluroxene 
(Section 5. 1 ) and AIA (Section 1.8.1.3 )). The destruction of cyto-
chrome P-450 by halothane does not however appear to arise from lipid 
peroxidation since all experiments performed..:!.!!_ vitro were in the 
presence of EDTA, an inhibitor of lipid peroxidation (312). Further-
more, thymol, which is the antioxidant used at 0.01% to preserve halo-
thane, and is a potential inducer of lipid peroxidation, did not cause 
a measurable change in the levels of cytochrome P-450 ..:!.!!_ vitro in the 
presence of microsomes, and NADPH-generating system plus EDTA (cf. 
Section 3.3 ) (results not shown). 
As proposed in Section 1.3.2 , the halothane mediated decrease of 
hepatic cytochrome P-450 appears to reflect in part the ability of halo-
thane to degrade the haem moiety of cytochrome P-450 and in part its 
ability to facilitate the dissociation of haem from the active site of 
cytochrome P-450 (16). Our observation that the losses of microsomal 
cytochrome P-450 exceeded the losses of microsomal haem (in nmoles per 
mg of microsomal protein) after incubation of halothane with hepatic 
microsomes for 25-30 min in vitro (Table 4.33 ) was consistent with 
the above proposal. Furthermore, significant levels of cytochrome 
P-420 (Fig. i.10 ) were produced after halothane treatment..:!.!!_ vivo+ 
and in vitro (Figs. 4.3 ~ 4.4 ) (Tables 4.21 , 4.24 , 4.25 , 4.34 ). 
The halothane mediated degradation of the haem moiety of cytochrome 
P-450 appeared to be a more rapid process than the dissociation of the 
+ The amount of cytochrome P-420 produced after halothane treatment in 
viv12_ is apparently too small to cause a significant difference between 
the losses of hepatic microsomal cytochrome P-450 and haem (Tables 4.21 , 
4. 24 ) . 
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haem from apocytochrome P-450 in vitro and in vivo. After incubation 
in the presence of halothane .:!.!!. vitro the losses of microsomal cyto-
chrome P-450 and haem (in nmoles per mg of microsomal protein) were 
initially equivalent but subsequently (after incubation of halothane 
with microsomes for 25-30 min), the loss of hepatic cytochrome P-450 
exceeded the loss of microsomal haem (Table 4.33). Furthermore, sig-
nificant levels of cytochrome P-420 were only produced at 5 and 10 hours 
after halothane treatment.:!.!!. vivo (Table 4.25) although the halothane 
mediated degradation of cytochrome P-450 was maximal 1 hour after halo-
thane treatment in vivo (Table 4.24 ). 
The effects of halothane on hepatic cytochrome P-450 and the significant 
changes in the rates of hepatic haem biosynthesis and biodegradation 
observed after acute halothane treatment.:!.!!. vivo appeared to be related 
as follows: 
At or prior to l hour after acute halothane treatment.:!.!!. vivo, halo-
thane caused a significant and equivalent decrease in the levels of 
hepatic microsomal cytochrome P-450 and haem (Tables 4.24 , 4.36 ). 
As proposed above, the initial effect of halothane on hepatic micro-
somal cytochrome P-450 appears to be degradation of the haem moiety of 
the enzyme, which would be expected to result in a decrease in the 
levels of haem in the central haem pool which regulates the activities 
of hepatic ALA-synthetase and haem oxygenase (Section 1.6 ). Therefore. 
the levels of ALA-synthetase would be anticipated to be initially 
increased after acute halothane treatment in vivo, as was observed 
(Table 4.26 ). Furthermore, in agreement with this proposal, a smaller 
-
increase in the activity of hepatic haem oxygenase was observed at 1 hour 
than at 5 and 10 hours after acute halothane treatment (Table 4.26). 
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At some time between l and 5 hours after acute halothane treatment l!:!_ vivo, 
halothane appeared to facilitate the dissociation of the haem from apo-
cytochrome P-450 (as indicated by the significant increase in cytochrome 
P-420 at 5 hours after acute halothane treatment (Table 4.25 )). This 
effect together with the increase in ALA-synthetase activity would cause 
an increase in the levels of free haem in the regulatory haem pool, and 
as a result, the activity of ALA-synthetase decreased to control levels 
and below (Table 4.26 ), whereas the activity of hepatic haem oxygenase 
was increased at 5 and 10 hours after acute halothane treatment in vivo 
(Table 4.26 ). 
The above proposals are consistent with the results obtained 24 hours 
after acute halothane treatment (Tables 4.21, 4.22, 4.23). Firstly, the 
leve1s of hepatic microsomal cytochrome P-450 and haem remain depressed at 
24 hours, as seen at earlier times, viz. l, 5 and 10 hours after halothane 
treatment (Tables 4.21 and 4.24 ). Secondly, the small or negligible 
effect of acute halothane treatment on the levels of urinary haem pre-
cursors (Table 4.23 ) was consistent with the relatively short time 
period (< 4 hours) over which the transient increase in the activity of 
ALA··synthetase was maintained (Table 4.22 , 4.26 ). Finally, the 
activity of hepatic haem oxygenase remained elevated at 24 hours, as 
at 5 and 10 hours after acute halothane treatment (Tables 4.21 , 4.26 ). 
The effects of acute halothane treatment on hepatic haem metabolism 
thus appeared to be consistent with the proposal that the halothane 
mediated decrease in cytochrome P-450 initially reflected the degrada-
tion of the haem of cytochrome P-450 followed by the dissociation of the 
holoenzyme. In order to further assess the proposed multiple effects 
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of acute halothane treatment on hepatic cytochrome P-450 and hepatic haem 
metabolism the levels of the enzyme, tryptophan pyrrolase, were deter-
mined after acute halothane treatment in vivo (Table 5.2 ). 
Tryptophan pyrrolase is a haem containing enzyme whose haem saturation 
levels are thought to be closely associated with the amount of haem in 
the regulatory haem pool (314-316). The haem saturation ratio of 
tryptophan pyrrolase was determined at the times corresponding to the 
previous measurements of the levels of cytochrome P-450, haem oxygenase 
and ALA-synthetase, viz. at 0, 1 and 5 hours after acute halothane treat-
ment. At l hour after acute halothane treatment, no change in the haem 
saturation ratio of tryptophan pyrrolase was observed, whereas at 5 hours 
after acute halothane treatment the haem saturation ratio of tryptophan 
pyrrolase was strikingly increased (Table 5.2). These results provide 
strong support for the proposed effects of halothane on cytochrome P-450 
and haem metabolism. The increase in the haem saturation ratio of tryp-
tophan pyrrolase 5 hours after acute halothane treatment is indicative 
of an increase in haem levels in the regulatory haem pool, presumably as 
a result of the halothane mediated dissociation of cytochrome P-450. 
Furthermore, no change in the haem saturation ratio of tryptophan 
pyrro1a3~ wa; observed 1 hour after acute halothane treatment which 
support~d the proposal that the dissociation of cytochrome P-450 by 
halothane occurred between 1 and 5 hours after acute halothane treatment. 
Although a decrease in the haem saturation ratio of tryptophan pyrrolase 
was expected 1 hout after acute halothane treatment due to the halothane 
mediated degr3dation of cytochrome P-450, the decrease in hepatic haem 
levels associated with this event may have occurred prior to this time 
point or have been too transient to be observed by this assay. 
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TABLE 5.2 
THE EFFECTS OF ACUTE HALOTHANE TREATMENT ON THE HAEM SATURATION RATIO 
OF HEPATIC TRYPTOPHAN PYRROLASE IN PHENOBARBITAL INDUCED RATS IN VIVO 
Rats were induced with phenobarbital (80 mg/kg for one day) and treated 
or not with one halothane injection (1 ml/kg) 24 hours later,at time 
zero. All rats were starved immediately after phenobarbital treatment 
and sacrificed at the times after the halothane treatment indicated or 
at an equivalent time in controls. The haem saturation ratio of tryptophan 
pyrrolase was determined as described by Badaway (314). Each value 
corresponds to determinations in duplicate or more on a group of 3 rats. 
HOURS 
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Abbreviations: mic., microsomal; HSR, haem saturation ratio 
* HSR represents holoenzyme activity/apoenzyme activity. 
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From the above results (Table 5.2) and the results presented in 
Section 4.7, it appeared that acute halothane treatment initially (ca. 
O - 1 hour after halothane treatment) mimics AIA treatment of animals 
in that it induced the activity of ALA-synthetase presumably as a con-
sequence of its ability to degrade the haem moiety of cytochrome P-450 
(cf. AIA, Section 1.8. 1.3). Subsequently (ca. 1-5 hours after halothane 
treatment) the effects of halothane on hepatic haem metabolism were 
similar to the effects of carbon disulphide on these processes (Section 
1.9 ), viz. halothane appeared to facilitate the dissociation of the 
haem of cytochrome P-450 and thereby increased the levels of haem in 
the regulatory pool, resulting in the increased activity of hepatic 
haem oxygenase and the normal or decreased activity of ALA-synthetase. 
Whereas the effects of carbon disulphide on hepatic cytochrome P-450 
and ~n hepatic haem metabolism are associated with the carbon disulphide 
mediated covalent modification of the apoprotein moiety of cytochrome 
P-450 (Section 1.9), the effect of halothane on apocytochrome P-450 is 
unknown and may reflect either denaturation or covalent modifications of 
apocytochrome P-450 (Fig. 5. 1 ) • 
Chronic halothane treatment was found to cause the rates of hepatic haem 
metabolism to oscillate as a function of time (Tables 4.27 - 4.32 ). 
The activity of ALA-synthetase and the levels of the urinary haem pre-
cursors \1ere increased after two injections of halothane (Tables 4.28 -
4.32 ) \vhich may result from the following circumstances: The ability 
of a single injection of halothane to decrease the levels of hepatic 
microsomal cytochrome P-450 and to increase the activity of hepatic haem 
oxygenase (Table 4.21 ) plus, perhaps, the reinforcement or extension 
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Fig. 5.1 
The proposed effects of halothane on the apoprotein moiety of hepatic 
microsomal cytochrome P-450 
Halothane 
(i) denaturation 
D + APO 
Halothane 
.,.(_i ,_,· ),--c-ov_a_,,l,_e_n_t ___ D + X-APO 
modification 
Q-APO represents unchanged cytochrome P-450 
D represents the haem moiety of cytochrome P-450 
APO represents the apoprotein moiety of cytochrome P-450 
X-APO represents a covalent modification of apocytochrome P-450 
of thts effect by a second injection of halothane (Table 4.27 ) would 
be expected to deplete haem from the regulatory haem pool. This process 
would lead to the observed increased activity of hepatic ALA-synthetase 
and con3equently to increased flux through the haem biosynthetic pathway, 
as evidenced by the observed increases in the levels of urinary haem 
precursors (Tables 4.28 - 4.31 ). At a subsequent time (viz. after the 
sixth injection of halothane), the increased flux through the haem bio-
synthetic pathway would be anticipated to increase the levels of haem 
in the regulatory haem pool to normal levels and to result in the 
return of the activities of hepatic ALA-synthetase and haem oxygenase 
to control levels (Tables 4.27 , 4.32 ). After the tenth injection of 
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halothane, the cycle would appear to be initiated once again, since 
increased flux through the haem biosynthetic pathway (viz. elevated 
levels of urinary ALA and porphobilinogen) was observed (Tables 4.28, 
4.29 ). 
The levels of hepatic microsomal cytochrome P-450 and haem remained 
low throughout the duration of the experiment presumably as a result 
of the continued destruction of cytochrome P-450 by halothane (Table 
4.27 ). 
The effects of chronic halothane treatment on haem biosynthesis and bio-
degradation were in striking contrast to the effects of chronic fluroxene 
treatment on these processes. Chronic fluroxene treatment resulted in 
a decrease in the activity of hepatic uroporphyrinogen synthetase and 
increases in the activity of hepatic ALA-synthetase and in the levels of 
urinary f1LA and porphobil i no gen, thus inducing an experimenta 1 porphyri a 
which.ciosely resembled Acute Intermittent Porphyria (Section 5.1 ). 
In cant~ast, chronic halothane treatment resulted in cyclical changes 
in haem metabolism and as a result did not produce consistent striking 
effects on hepatic haem metabolism nor did it induce a state of 
porphyria in experimental animals. These contrasting results are 
propos€d to arise as a consequence of the differing effects of fluroxene 
and halothane on hepatic cytochrome P-450 (cf. Sections 1.3.1 , 1.3.2 ~ 
5.1, 5,3 ). 
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5.4. CONCLUSION 
The destruction of cytochrome P-450 by various xenobiotics plays an 
important role in their ability to affect hepatic haem metabolism. 
However, compounds which destroy hepatic microsomal cytochrome P-450 
by different mechanisms appear to affect hepatic haem metabolism in 
different ways, as follows: 
Compounds such as fluroxene and trichloroethylene which destroy the 
haem moiety of cytochrome P-450 cause increases in the rates of hepatic 
haem biosynthesis and/or haem biodegradation (Sections 5.1 , 5.2 ). 
Specific differences in the degradation of cytochrome P-450 haem by 
these two compounds appear to be responsible for the different effects 
of these compounds on hepatic haem metabolism; a single injection of 
fluroxene causes the induction of both hepatic haem biosynthesis and 
biodegradation (Section 5.1 ), whereas acute trichloroethylene admin-
istration results in an increase in hepatic haem biodegradation but 
little or no change in hepatic haem biosynthesis (Section 5.2 ). 
In contrast, chemicals such as halothane, which appear to cause both the 
degradation and the dissociation of cytochrome P-450 result in cyclical 
changes in hepatic haem biosynthesis and haem biodegradation in a manner 
which corresponds to the differing effects of this compound on cytochrome 
P~450 (Section 5.3 ). 
Although the effects of acute administration of these compounds on 
hepatic microsomal cytochrome P-450 appear to play an important role in 
determining their effects on hepatic haem metabolism, the effects of 
chronic administration of the anaesthetic agents on hepatic haem bio-
synthesis appear to result from the effects of these compounds on enzymes 
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of the haem biosynthetic pathway and/or their effects on cytochrome P-450. 
Whereas fluroxene and trichloroethylene appeared to inhibit specific 
enzymes of the haem biosynthetic pathway, viz. uroporphyrinogen synthetase 
and uroporphyrinogen decarboxylase respectively. Halothane did not appar-
ently affect a particular enzyme of haem biosynthesis. Since a block 
in the haem biosynthetic pathway results in the induction of ALA-synthetase 
and a buildup of haem precursors before the enzymatic block, administra-
tion of these and other chemicals which inhibit a particular 
enzyme of haem biosynthesis, results in the induction of a state 
of experimental porphyria in animals which may resemble a particular 
type of human genetic porphyria. For example, fluroxene administration 
which resulted in the inhibition of uroporphyrinogen synthetase and an in-
crease in ALA-synthetase activity as well as increased levels of urinary ALA 
and porphobilinogen, induced an experimental porphyria in animals which 
closely resembled Acute Intermittent Porphyria (AIP) {Section 5.1 ). 
Similarly, chronic trichloroethylene treatment appeared to affect the 
haem biosynthetic enzyme uroporphyrinogen decarboxylase since increased 
leve1s of urinary ALA, porphobilinogen and particularly uroporphyrin and 
coproporphyrin were observed. These results suggested that chronic tri-
chloroethylene induced an experimental porphyria in animals which 
resembled human Porphyria Cutanea Tarda (PCT) (Section 5,2 ). 
In contrast, halothane did not appear to affect any particular enzyme of 
haem b:iosynthesis, but caused cyclical changes in hepatic haem metabolism. 
Since halothane did not produce consistent striking effects on haem 
metabolism, it did not induce a state similar to human genetic porphyria 
in experimental animals (Section 5.3). 
From the results presented in this thesis, it is clear that the effects 
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of chemicals on hepatic microsomal cytochrome P-450 and hepatic haem 
metabolism are extremely varied and appear to depend on several factors 
which may include one or more of the following: 
(a) The life-time of the drug in the body, viz. its lipid-solubility 
and rate of metabolism; 
(b) The pathways for the metabolism of the drug, e.g. halothane is 
metabolized via both oxidative and reductive pathways which are 
both thought to produce reactive species capable of destroying 
cytochrome P-450 (Section 1.2.3 ); 
(c) The various forms of cytochrome P-450 involved in the metabolism of 
the suicide substrates, e.g. for fluroxene, the 3-methylcholanthrene-
inducible form of cytochrome P-450 appears to metabolize fluroxene 
slowly but to be more susceptible to degradation by fluroxene than 
other forms of the enzyme in rats pretreated with phenobarbital (132); 
(d) The extent of degradation of cytochrome P-450 by the drug; 
(e) The nature of the modification of cytochrome P-450 by the drug: 
i.e., is the haem and/or the apoprotein moieties modified: Is 
th€ haem moiety of cytochrome P-450 converted to green pigments 
viz. N·alkylated porphyrins, or is its breakdown to mono- or 
dipyrroles or smaller fragments enhanced. 
(f) The ability of the drug to affect or not a particular enzyme of 
the haem biosynthetic pathway. 
Obviously, in view of the complexity of the factors affecting the relation-
ship between the degradation of hepatic cytochrome P-450 and its sub-
sequent effects on haem metabolism, it is not possible at this time to 
predict the detailed effects of a drug on haem metabolism in vivo. It 
is, however, clear that chemicals which destroy hepatic microsomal cyto-
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chrome P-450 will in general affect hepatic haem metabolism as follows: 
Chemicals which stimulate the dissociation of cytochrome P-450 are 
expected to increase hepatic haem biodegradation, whereas chemicals 
which degrade the haem moiety of cytochrome P-450 are expected to 
increase haem biosynthesis. The specific details of their effects on 
hepatic haem metabolism will be influenced by the variables described 
above. 
Consistent with these general proposals is the observation that the 
widely used contraceptive agents, norethisterone and ethynylestradiol, 
which modify the haem moiety of hepatic cytochrome P-450 to green 
pigments (317, 318), increase hepatic haem biosynthesis (318). Further-
more, a variety of drugs including griseofulvin, morphine and the inter-
feron inducing agents, tilorone and polyriboinosinic acid.polyribocyti-
dylic acid, destroy hepatic microsomal cytochrome P-450 and affect hepatic 
haem metabolism in vivo (319-322). --·-. 
From the evidence available in the literature, together with the results 
presented in this thesis, it is anticipated that chemical agents which 
are known to destroy cytochrome P-450 such as the widely used industrial 
agents bromoethane and 1,1 ,l-trichloroethane, cis- and trans-dichloro-
ethylene (324), as well as compounds which contain an allyl group such 
as allyl bromide~ allyl chloride, allyl isothiocyanate (16) and the 
CO!Thil0n1J used drug, secobarbitone (323), may produce pronounced effects 
on hepatic haem metabolism in vivo. 
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